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ABSTRACT 
 
Daniel Earl Cooper: Physiological Consequences of Compartmentalized Glycerolipid 
Synthesis 
(Under the direction of Rosalind A. Coleman) 
 
 
The metabolic derangements present in type 2 diabetes are associated with the 
accumulation of triacylglycerol (TAG) in adipose and non-adipose tissues.  However, 
the mechanisms whereby TAG accumulation drives pathogenesis remain obscure.  The 
synthesis of TAG and other glycerolipids is initiated by the rate-limiting enzyme, 
glycerol-3-phosphate acyltransferase (GPAT), which catalyzes the esterification of an 
acyl-CoA to the sn-1 position of the glycerol-3-phosphate backbone.  Four mammalian 
GPAT isoforms, each the product of a separate gene, have been discovered and recent 
evidence suggests that each GPAT isoform performs a unique function in directing 
glycerolipid synthesis.  To test this hypothesis, we investigated the role of different 
GPAT isoforms in liver and brown adipose lipid metabolism, and adipocyte 
differentiation.  First, we compared the unique functions of the major hepatic GPAT 
isoforms, GPAT1 and GPAT4.  Although these isoforms contribute a similar amount of 
total GPAT activity in liver, GPAT1, but not GPAT4, was required for the incorporation of 
de novo synthesized fatty acids (FA) into TAG and to divert FA away from β-oxidation.  
Next, we elucidated the mechanism whereby mice lacking GPAT4 are protected from 
diet-induced obesity.  GPAT4 is a major GPAT isoform in BAT, comprising 
approximately 65% of the total GPAT activity.  In primary brown adipocytes lacking 
	   iv	  
GPAT4 exogenous oleate was oxidized at a 46% higher rate than controls, suggesting 
that Gpat4-/- mice are protected from diet-induced obesity because GPAT4 in brown 
adipose tissue is required to limit the oxidation of exogenous FA.  Finally, we provide 
evidence that the lipodystrophy-associated protein Seipin is an evolutionarily conserved 
regulator of GPAT activity. Seipin and its yeast ortholog, Fld1, physically interacted with 
GPAT and the loss of Seipin was associated with increased GPAT activity because 
GPAT had a higher affinity for one of its substrates, glycerol-3-phosphate.  Seipin 
deficiency impairs adipogenesis and alters lipid droplet morphology and in 3T3L1 
preadipocytes, GPAT overexpression recapitulated these effects, suggesting that 
increased GPAT activity is the underlying cause of the impaired adipogenesis and 
altered lipid droplet morphology.  Taken together, these results suggest that the 
functions of each GPAT isoform are linked to specific physiological processes and that 
glycerolipid synthesis is highly compartmentalized. 
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CHAPTER I: INTRODUCTION 
 
The worldwide prevalence of obesity has reached epidemic proportions and in 
the US alone, the treatment costs of obesity-associated co-morbidities comprise 10% of 
total health care expenditures (1-3).  The metabolic syndrome, encompassing a set of 
conditions including obesity, insulin resistance, cardiovascular disease, and 
hyperlipidemia, is highly associated with the accumulation of excess triacylglycerol 
(TAG) in liver, skeletal muscle, and adipose tissue (4).  Despite this association, little is 
known about the regulation of TAG synthesis in response to changes in dietary 
composition or nutritional status.  Thus, understanding the basic mechanisms of TAG 
synthesis under different physiological conditions may provide insight into the 
relationship between metabolic disease and TAG accumulation. 
 
The initial and rate-limiting step in the synthesis of TAG and phospholipids is 
catalyzed by glycerol-3-phosphate acyltransferase (GPAT; EC 2.3.1.15).  GPAT 
esterifies a fatty acyl-CoA to the sn-1 position of a glycerol-3-phosphate backbone to 
produce lysophosphatidic acid.  Four mammalian GPAT isoforms, each the product of a 
separate gene, have been discovered and differ in their subcellular location, response 
to nutritional stimuli, substrate preference, and tissue expression pattern.  Although the 
presence of four distinct enzymes that catalyze the same biochemical reaction appears 
redundant, a growing body of evidence supports the hypothesis that each GPAT 
isoform performs a unique function in glycerolipid synthesis. 
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Consistent with this hypothesis, mice with deleted GPATs express vastly different 
phenotypes.  GPAT1-deficient mice are protected from diet-induced hepatic steatosis 
and insulin resistance, have increased hepatic fatty acid oxidation, and are protected 
from diethylnitrosamine-induced hepatocellular carcinoma (5-8).  Although a mouse 
model deficient in GPAT2 has not been reported, its expression in testis suggests a 
function for GPAT2 in that tissue (9).  GPAT3 is highly expressed in adipose tissue, 
comprising approximately 80% of the total GPAT activity in that tissue, however, Gpat3-
/- mice are not lipodystrophic and, when fed a high-fat diet, gain weight normally (10,11).  
GPAT4 is highly expressed in liver and BAT, comprising approximately 45% and 65% of 
the total GPAT activity, respectively (12).  GPAT4 is also highly expressed in mammary 
gland, where its deficiency prevents normal mammary gland development and 
decreases milk TAG and DAG content (13).  Mice lacking GPAT4 are protected from 
diet-induced obesity and insulin resistance (14).  In addition, Gpat4-/- mice lack a 
subdermal adipose tissue layer, and their metabolic rate was 5% higher than controls 
(15).  Vergnes et al. attributed the metabolic phenotype to the lack of subdermal 
adipose tissue; however, it remains unclear whether the lack of subdermal adipose 
tissue was the cause of or an adaptation to a higher metabolic rate.  Because each 
GPAT isoform catalyzes the same enzymatic reaction, it is likely that many of the 
phenotypic differences in GPAT-null animals are due to differences in subcellular 
location, nutritional regulation, or tissue expression patterns.  
 
The focus of this dissertation is to investigate how these differences in GPAT 
isozymes result in unique functions within a physiological context.  In chapter III, we 
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investigate the unique functions of the major hepatic GPAT isoforms, GPAT1 and 
GPAT4.  Results from this study provide evidence that GPAT1, but not GPAT4, is 
required for the incorporation of de novo synthesized fatty acids into TAG and to divert 
fatty acids away from β-oxidation.  The purpose of Chapter IV is to elucidate the 
mechanism whereby mice lacking GPAT4 are protected from diet-induced obesity.  
Findings from this study suggest that Gpat4-/- mice are protected from diet-induced 
obesity because GPAT4 in brown adipose tissue is required to limit the oxidation of 
exogenous fatty acids.  Preliminary findings in Chapter V suggest that the microsomal 
GPATs are regulated by an ER-protein, Seipin, and that this interaction is conserved 
from yeast to mammalian tissues.  The loss of Seipin increased GPAT activity because 
in the absence of Seipin, GPAT had a higher affinity for one of its substrates, glycerol-3-
phosphate.  This study is the first to identify a protein that directly interacts with GPAT to 
alter its activity.  Taken together, these results provide indirect evidence suggesting that 
pathways of glycerolipid synthesis are highly compartmentalized and that this 
compartmentalization is an important mechanism for responding to physiological stimuli. 
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CHAPTER II: BACKGROUND 	  
The compartmentalized metabolism hypothesis 	  
Meeting the complex physiological demands of mammalian life requires strict 
control of fatty acyl-CoA metabolism.  Acyl-CoA synthetases must activate fatty acids to 
form acyl-CoAs before they can be used for energy production in mitochondria and 
peroxisomes, stored as triacylglycerol, cholesterol esters, and retinol esters in lipid 
droplets, esterified to form membrane phospholipids, or activate transcription factors 
and signaling pathways.  Indirect evidence suggests that acyl-CoAs do not wander 
freely within cells, but instead, are channeled into specific downstream pathways.   
 
Intracellular signaling cascades are typically depicted as a series of protein-
protein interactions that act as scaffolds to bridge two intracellular compartments or 
span across membrane bilayers.  In contrast, metabolic pathways are presented as a 
linear sequence of steps occurring in a virtually empty cytosolic space.  In reality, the 
cytosol is a dense non-homogeneous network of proteins and metabolites fighting for 
space (16).  Considered in this view, several potential mechanisms might mediate the 
flux of metabolites among and between intracellular compartments.  First, metabolic 
enzymes are likely found in complexes; either arranged very close together or directly 
interacting.  Second, in response to various physiological stimuli membrane-organelles 
might reorganize to permit interaction of enzymes from different organelles.  Third, 
selective movement of enzymes from one membrane to another, similar to that of TAG 
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synthetic enzymes moving from the ER to the leaflet of lipid droplets, may aid in 
compartmentalization.  Before we can investigate these mechanisms, further work is 
required to understand the relationship between various metabolic enzymes and the 
physiological processes they mediate.  The focus of this dissertation is to understand 
the physiological consequences of compartmentalized glycerolipid synthesis. 
 
The Kennedy Pathway for glycerolipid synthesis 
   
One predominant pathway whereby acyl-CoAs are metabolized is in the 
synthesis of complex lipids.  Although initially thought to be a random process, recent 
evidence suggests that glycerolipid synthetic enzymes influence the flux of acyl-CoAs to 
specific fates within the cell.  During the early 1950s and 60s, Eugene Kennedy and 
colleagues identified a series of enzymatic steps required for the synthesis of glycerol-
containing lipids, including triacylglycerol and phospholipids (PL). The initial and rate-
limiting step in the synthesis of TAG and PL is performed by glycerol-3-phosphate 
acyltransferase (GPAT), and this enzyme catalyzes the addition of an acyl-CoA to the 
sn-1 position of glycerol-3-phosphate to form lysophosphatidic acid (LPA) (17).  The 
esterification of a second acyl-CoA at the sn-2 position of LPA, catalyzed by 
acylglycerol-3-phosphate acyltransferase (AGPAT), results in the formation of 
phosphatidic acid (PA).  Subsequent dephosphorylation of PA by Lipin/phosphatidic 
acid phosphohydrolase (PAP) and the esterification of a third acyl-CoA by diacylglycerol 
acyltransferase (DGAT) culminates in the formation of TAG.  Alternatively, 
diacylglycerol can be used in the formation of phosphatidylethanolamine and 
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phosphatidylcholine by the enzymes CDP-ethanolamine phosphotransferase and CDP-
choline phosphotransferase, respectively (Fig 2.1) (18).   
 
Since these initial discoveries, further work has elucidated a number of distinct 
isozymes for each step in the Kennedy Pathway.  Thus, the number of enzymes and 
diverse set of glycerolipid products suggests the need for a complex regulatory network 
to meet the demands of individual cells, tissues, and whole organisms.  Because it 
possesses the lowest enzymatic activity of Kennedy Pathway enzymes, GPAT is 
positioned at a key regulatory point in the flux of acyl-CoAs and glycerol-3-phosphate 
toward glycerolipids. 
	  
Figure 2.1 The Kennedy Pathway for glycerolipid synthesis.	  	  GPAT, glycerol-3-
phosphate acyltransferase; AGPAT, 1-acylglycerol-3-phosphate acyltransferase; PAP, 
phosphatidic acid phosphohydrolase; DGAT, diacylglycerol acyltransferase; CPT, CDP-
Choline:diacylglycerol cholinephosphotransferase; EPT, CDP-
Ethanolamine:diacylglycerol ethanolaminephosphotransferase.	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GPATs are members of the acyltransferase family of enzymes 	  
Four mammalian GPAT isoforms, each the product of a separate gene, have 
been discovered and identified as members of the pfam 01553 family of glycerolipid 
acyltransferases.  The GPAT proteins possess two transmembrane domains, four 
conserved acyltransferase motifs, and their active sites face the cytosol (19) (Fig 2.2).  
The mutagenesis of invariant residues within these motifs confirmed that these regions 
are required for the activity of Escherichia coli (E. Coli) GPAT and mouse GPAT1 
(20,21).  In E. coli, the invariant histidine and aspartate in motif I, glycine in motif III, and 
proline in motif IV are essential for catalysis.  The invariant phenylalanine and arginine 
in motif II and glutamate and serine in motif III are essential for glycerol-3-phosphate 
binding (Table 2.1).  In murine GPAT1, Arg-318 is required for maximal GPAT catalysis 
(21).  Leading to their initial identification as AGPAT isoforms, both microsomal GPAT 
isoforms, GPAT3 and GPAT4, possess a fifth motif, similar to that in AGPAT1 and -2.  
However, subsequent studies confirmed that GPAT3 and 4 possess GPAT activity and, 
thus, were reclassified as GPATs (10,12,22). 
	  
Figure 2.2: Acyltransferase motifs, active site, and predicted transmembrane 
domains of murine GPAT isoforms.  Black bars indicate active site.  Yellow bars 
represent acyltransferase motifs.  Dark blue illustrates the transmembrane domains. 
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Although these acyltransferase motifs are highly conserved from E. coli to 
rodents, the presence of four distinct GPAT isoforms is only observed in vertebrates 
(23).  Comparative genomic and phylogenetic analyses have suggested that small-scale 
duplication events in vertebrates are responsible for the divergence of GPAT1 and 
GPAT2 as well as splits for GPAT3 and GPAT4 (23).  In support of the hypothesis that 
GPAT isozymes perform distinct functions, previous work in genetics suggests that 
compared to whole-genome duplications, small-scale duplication events support a 
greater likelihood for novel functions (24).  
 
 
Table 2.1: Acyltransferase homology blocksa 
 Block I Block II Block III Block IV Accessionb  
GPAT 303c 348 382 417  
E. coli VPCHRSHMDYLLL GAFFIRR YFVEGGRSRTGR ITLIPIYI 130326 
H. influenza VPCHRSHMDYLLL GAFFIRR YFVEGGRSRTGR ISIVPVYV 1172533 
M. turberculosis AFSHRSYLDGMLL GAIFIRR WSIEGGRTRTGK VYLVPTSI 2791522 
C. elegans ICLHRSHLDILSM NTIFIRR FFLEGTRSRFGK ISIIPVVF 1458332 
M. musculus LPVHRSHIDYLLL GGFFIRR IFLEGTRSRSGK ILVIPVGI 2498786 
R. norvegicus LPVHRSHIDYLLL GGFFIRR IFLEGTRSRSGK ILVIPVGI 2444459 
      
GPAT consensus φ--HRS-φDφφ-- G—φFIRR φFφEGTRSR-GK φφφφPφφφ  
aBlocks of homology were identified on the basis of amino acid alignments using the 
CLUSTAWL algorithm.  bAccession numbers are for the National Center for 
Biotechnology Information Protein Database.  cNumbers indicate the amino acid residue 
number at the beginning of each block in E. coli GPAT. 
 
 
GPAT isoform subcellular location, tissue distribution, nutritional regulation, and 
acyl-CoA preference 
 
GPAT1 
 
 GPAT1 is the best-characterized GPAT isoform.  GPAT1 is primarily localized to 
the outer mitochondrial membrane (Fig 2.3), possesses two transmembrane domains, 
and its active site faces the cytosol (25,26).  Murine GPAT1 contains 828 aa, nearly 
	  	   9	  
twice the size of GPAT3 and 4, and the extra C-terminal region of GPAT1 interacts with 
the active site region and is required for activity (27).  The role of this C-terminal tail in 
cells or whole animals has not been further investigated.    
 
	  
Figure 2.3: GPAT isozyme subcellular location.  GPAT1 and GPAT2 are localized to 
the outer mitochondrial membrane whereas GPAT3 and GPAT4 are located on the 
endoplasmic reticulum. 
 
In rodents, GPAT1 is most highly expressed in the liver, where it comprises 
between 20-50% of the total GPAT activity (5).  In other tissues, GPAT1 is responsible 
for approximately 10% of the total GPAT activity (28).  Following a 48 h fast, GPAT1 
protein and activity in liver and adipose tissue are reduced 30-50% and when refed with 
a high sucrose diet for 24 h both protein amount and activity overshoot fed-state levels 
by 30-60% (29).  Consistent with its regulation in response to nutrient status, AMP-
activated kinase, active under conditions of low energy, was suggested to 
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phosphorylate GPAT1 and inhibit its activity (30).  GPAT1 possesses a strong 
preference for saturated acyl-CoA and its activity is resistant to inhibition by sulfhydryl 
reagents (18,31).  Based upon its high activity for saturated acyl-CoAs and the 
observation that the sn-1 position of most phospholipids contains saturated fatty acids, it 
is inferred that GPAT possesses an sn-1 preference for esterification of an acyl-CoA to 
the glycerol-3-phosphate backbone.  It should also be noted that the acyl-CoA 
preference for GPAT has not been directly compared, but inferred based upon the high 
proportion of saturated fatty acids in the sn-1 position.  Confirming a functional 
regulation of GPAT1 by sterol regulatory element binding protein 1c (SREBP1c), 
GPAT1 deficiency in ob/ob mice did not restore insulin sensitivity, but did prevent 
hepatic steatosis (32).  Consistent with these findings, in HepG2 cells, SREBP1c 
dramatically increased GPAT1 promoter activity, suggesting that GPAT1 is a key 
element in the SREBP1c-mediated increase in lipogenesis (33).   
 
GPAT2 
 
GPAT2 is located on the outer mitochondrial membrane, possesses two 
transmembrane domains and its N and C-terminal regions face the cytosol (34).  
GPAT2 is most highly expressed in spermatic germ cells and GPAT2 overexpression in 
CHO-K1 cells increased the incorporation of [1-14C]arachidonate into TAG, suggesting 
a preference for 20:4-CoA as an acyl donor (9).  Consistent with a role for GPAT2 in 
arachidonyl-CoA metabolism, GPAT2 overexpression increases GPAT and AGPAT 
activity 2-fold when arachidonyl-CoA is used as the acyl donor, suggesting that GPAT2 
might be able to acylate both glycerol-3-phosphate and lysophosphatidic acid.  In 
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contrast, when other saturated or unsaturated acyl donors are used, GPAT2 
overexpression does not change GPAT activity (9).  GPAT2 has been identified as a 
cancer testis gene that promotes growth in the breast cancer cell line, MDA-MB-231 
(35).  However, the mechanism whereby GPAT2 mediates tumorigenicity remains 
obscure. 
  
 
GPAT3 
 
 GPAT3 is located on the endoplasmic reticulum and is highly expressed in white 
adipose tissue, comprising approximately 80% of the total GPAT activity in that tissue 
(11).  GPAT3 is also highly expressed in small intestine, kidney, and heart, however, its 
contribution to total GPAT activity in these tissues has not been determined (10).  Upon 
differentiation of 3T3L1 preadipocyte cells, GPAT3 mRNA is upregulated 70 to 100-fold, 
and insulin-dependent phosphorylation of GPAT3 increases its activity 1.5-fold (10,36).  
In 3T3L1 cells, shRNA-mediated knockdown of GPAT3 decreases GPAT activity and 
lipid accumulation, and reduces the expression of a number of adipogenic genes, 
suggesting a role for GPAT3 in adipogenesis (35).  In contrast to these observations, 
GPAT3 deficiency in mice does not affect white adipose tissue development or TAG 
accumulation, suggesting that further research is necessary to understand its role in 
WAT (11).   
 
GPAT4 
 
GPAT3 shares an 86.6% identical amino acid sequence to the second 
microsomal GPAT isoform, GPAT4 (12).  GPAT4 is located on the endoplasmic 
reticulum and the drosophila orthologue of GPAT4 is also found on the surface of 
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growing lipid droplets, suggesting that under specific conditions GPAT4 may move from 
the ER to the lipid droplet monolayer (37).  GPAT4 is a major GPAT isoform in BAT and 
liver, comprising 65% and 45% of the total GPAT activity in each tissue, respectively 
(38).  The activity of GPAT4 is highest with 16:0-CoA, followed by 18:0 and 18:2-CoA 
(12).  In contrast to GPAT3 deficiency, GPAT4 deficiency does not change GPAT 
activity in white adipose tissue (12).  Furthermore, shRNA-mediated knockdown of 
GPAT4 in 3T3L1 cells does not alter GPAT activity, lipid accumulation, or adipogenic 
gene expression during adipocyte differentiation (36), suggesting an alternate function 
for GPAT4 in white adipose tissue.   
Consistent with a tissue-dependent function of each GPAT isoform, in Cos-7 
cells, the overexpression of GPAT1 increases [1-14C]oleate incorporation into DAG and 
TAG.  In contrast, the overexpression of GPAT4 increases  [1-14C]oleate incorporation 
into DAG, but not TAG (38).  Because livers of chow-fed Gpat4-/- mice contain 45% less 
TAG than livers of wild type mice, we assume that GPAT4 in vivo initiates TAG 
synthesis and that Cos-7 cells might lack the necessary interacting partners to enable 
the esterification of excess GPAT4-derived DAG.  This observation suggests that each 
GPAT isoform may interact with specific downstream enzymes or enzyme complexes 
that contribute to their diverse functions.  A summary of these characteristics can be 
found in Table 2.2. 
 
 
 
 
	  	   13	  
 
 
 Table 2.2: Summary of subcellular location, tissue expression patter, nutritional 
regulation, and acyl-CoA preference. 
 
aindicates highest tissue expression in rodents.  OMM, outer mitochondrial membrane; 
ER, endoplasmic reticulum; LD, lipid droplet. 
 
 
 
 
 
 
Isoform Subcellular 
Location 
Tissue 
Expressiona 
Nutritional Regulation Acyl-CoA 
preference 
GPAT1 OMM Liver mRNA, protein, activity 
decreased by fasting, 
increased following 
refeeding with high 
sucrose diet 
 
activity increased 10-fold 
with 3T3L1 cell 
differentiation 
 
SREBP1c increases 
mRNA 
 
AMPK phosphorylates 
and inhibits activity 
Activity with 16:0-
CoA 2 to 3-fold 
greater than with 
18:0-CoA or 18:1 
CoA 
GPAT2 OMM Testis Unknown No preference for 
16:0-CoA over 
18:1-CoA 
GPAT3 ER white adipose, 
small intestine 
mRNA, protein, and 
activity dramatically 
increased with adipocyte 
differentiation 
 
insulin-dependent 
phosphorylation increases 
activity 
Not tested 
GPAT4 ER and LD Liver, Brown 
adipose, small 
intestine 
Insulin-dependent 
phosphorylation increases 
activity 
When 
overexpressed in 
Cos-7 cells 
activity was 
highest with 18:2-
CoA, followed by 
16:0-CoA, 18:0-
CoA, and 18:1-
CoA 
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Diverse phenotypes of GPAT-deficient mice  	  
Consistent with the hypothesis that each GPAT isoform performs a distinct 
function in directing acyl-CoAs toward glycerolipid synthesis, mice with deleted GPATs 
express vastly different phenotypes.  Mice lacking GPAT1 are resistant to diet-induced 
hepatic steatosis (but not weight gain) and insulin resistance, are protected from 
diethylnitrosamine-induced hepatocellular carcinoma, and have increased hepatic β-
oxidation (5,6,8,39).   In contrast, although GPAT4 comprises nearly 50% of total GPAT 
activity in liver and mice lacking GPAT4 have 45% less hepatic TAG than controls, 
hepatic β-oxidation in Gpat4-/- mice is unchanged.  This may be partially explained by 
the fact that Gpat4-/- mice are resistant to diet and genetically induced obesity and their 
metabolic rate is 4-6% higher than controls (40).  Thus, the reduction in hepatic TAG in 
Gpat4-/- mice is the result of an increase in whole-body energy metabolism.  
 
Despite the loss of 80% of total GPAT activity in white adipose, the mass of 
adipose tissue in mice lacking GPAT3 was normal in chow-fed mice and, with high-fat 
feeding, grew similar to controls (11).  Although GPAT activity in livers of Gpat3-/- mice 
was unchanged, the N-ethylmaleimide-sensitive GPAT activity was 30% lower than 
controls, suggesting compensation by mitochondrial GPAT1.  When fed a high-fat diet, 
cholesterol homeostasis in Gpat3-/- mice was abnormal, however, the mechanism for 
this abnormality remains unclear (11). 
 
  Mice with a targeted deletion of GPAT4 are born a normal size, at weaning 
weigh 25% less and are 10% shorter, and as adults, are resistant to diet and genetic-
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induced obesity and insulin resistance (14,15).  In contrast to other GPAT-null mice, 
energy expenditure in chow-fed Gpat4-/- mice is 4-6% higher than controls.  Consistent 
with an increase in global metabolic activity, Gpat4-/- male mice fed a chow diet 
accumulate less TAG in brown adipose, liver, and gonadal white adipose tissue than 
wild type mice.  At 12 weeks of age, Gpat4-/- mice fed a chow diet lack subdermal 
adipose tissue and Vergnes et al hypothesized that the lack of subdermal adipose 
tissue in Gpat4-/- mice increases heat loss through the skin and, thus, increases 
metabolic rate.  However, Gpat4-/- mice have normal cold tolerance, suggesting that 
even under extreme conditions, these mice are not losing excess heat.  Therefore, 
because the precise mechanism whereby Gpat4-/- mice are resistant to obesity remains 
unclear, we proposed to determine why the lack of GPAT4 protects mice from diet-
induced obesity.  Based upon the expression of GPAT4 in the BAT, the known role of 
GPATs in lipid synthesis, and the known function of brown adipose tissue, we 
hypothesized that lack of GPAT4 in BAT increases acyl-CoA availability for oxidation, 
activates PPARα and increases uncoupled mitochondrial oxidation (Fig 2.4).  Beyond 
this function for GPAT4, additional phenotypic characterization and direct comparisons 
of mice lacking GPAT isozymes are necessary to understand how each isoform 
contributes to glycerolipid biosynthesis in a physiological context. 
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Figure 2.4: Hypothesis about the role of GPAT4 in BAT metabolism.  We 
hypothesize that in the absence of GPAT4 in BAT, exogenous FA can be directly 
oxidized.  Because FA and acyl-CoAs are not metabolized to TAG, they are available to 
be oxidized, activate UCP1, uncouple oxidation from ATP synthesis and generate heat. 
 
Enzymes of the Kennedy Pathway are key regulators of energy metabolism 
   
Several of the acyltransferase-null mouse models are protected from diet-
induced obesity, suggesting that members of the acyltransferase family are key 
regulators of energy homeostasis (15,41-43). Unsurprisingly, the mechanism whereby 
lack of each acyltransferase confers resistance to obesity is related to the tissue 
expression and relative contribution to total enzyme activity in that tissue.   For example, 
a role for MGAT2 in TAG absorption was highlighted by its high expression and activity 
within enterocytes (44,45).  Absence of MGAT2 in mice results in delayed TAG 
absorption, uncoupled nutrient intake from insulin secretion, and increased total energy 
expenditure (42,46).  Similar to the GPAT isoforms, DGAT1 and DGAT2 are 
synthesized from separate genes and have unique tissue expression patterns.  The 
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absence of DGAT1 in mice reduces the rate of TAG absorption and protects mice from 
high fat diet-induced weight gain (43).  DGAT2 deficiency in the skin increases skin 
permeability and hair loss after puberty (47).  Together, these studies suggest a major 
role for acyltransferase enzymes in whole-body energy metabolism and highlight the 
importance of understanding the basic biological mechanisms linking triacylglycerol 
synthesis and metabolic efficiency. 
 
GPAT-derived lipid intermediates and insulin resistance 	  
 The metabolic syndrome, a group of metabolic derangements including insulin 
resistance, obesity, hyperlipidemia, and cardiovascular disease, is strongly associated 
with increased TAG accumulation in adipose and non-adipose tissues (4).  Classically, 
TAG synthesis has been thought to be a protective mechanism against the buildup of 
cytotoxic lipid metabolites.  However, recent discoveries demonstrate that intermediates 
of TAG synthesis are critical metabolites for modulating intracellular signaling, most 
notably, the insulin-signaling pathway (48-50).  Based upon these findings, the flux of 
lipids toward TAG can be considered an important source of signaling molecules that 
coordinates nutrient flux and intracellular signaling (Table 2.3).  Two lipid intermediates 
implicated in the insulin-signaling pathway are DAG and PA.  An abundance of 
evidence describes the role of these lipid intermediates in different reactions of the 
insulin-signaling pathway; DAG activates PKCε and PA dissociates the mTORC2 
complex (51-55).   
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Mitochondrial GPAT1 has been implicated in the generation of PA and DAG.  
First, hepatic overexpression of GPAT1 in mice increased hepatic DAG content, 
increased the amount of PKCε in membranes, and impaired insulin-dependent 
phosphorylation of IRS1/2 (48).  Inversely, GPAT1-deficient mice are protected from 
high-fat/high-safflower oil diet-induced hepatic steatosis and insulin resistance (6).  
Although PKC activity was not measured, these changes are associated with reduced 
hepatic DAG content and PKCε translocation to membranes.  In primary hepatocytes, 
GPAT1 overexpression increased intracellular DAG content, but also intracellular PA 
content (52).  In this model, the overexpression of GPAT1 led to increases in 16:0-
containing DAG and PA species and was associated with the dissociation of the 
mTORC2 complex, but insulin-dependent phosphorylation of IRS1/2 was unchanged.  
Similar results were observed with overexpression of GPAT4, but not GPAT3 (14).  
Specifically di-16:0 PA disrupted the association of the mTORC2 complex, impairing 
phosphorylation of AKT at Ser473 and Thr308 (14).  Furthermore, when Gpat1-/- and 
Gpat4-/- mice were fed the high-fat/high-safflower oil diet, they remained insulin sensitive 
and hepatic PA content was diminished relative to controls (14).  Although hepatic DAG 
content in Gpat1-/- and Gpat4-/- mice was lower than controls, PKCε activity and 
phosphorylation of IRS1/2 was unchanged. 
 
The discrepancies between these studies rest primarily with the methods for 
assessing PKCε activation.  The translocation of PKCε from the cytosol to membranes 
is required for its activation, however, this is not sufficient for PKCε activation (56).  In 
primary hepatocytes, increasing intracellular PA levels did increase the proportion of 
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PKCε located on the membrane, but PKCε activity remained unchanged.  Based upon 
these results, the authors concluded that PA, but not DAG, was responsible for 
impairing the insulin-signaling pathway.   
 
These results are not without caveats.  First, primary hepatocytes are often 
cultured in media containing 25 mM glucose, thus increasing de novo fatty acid 
synthesis and the amount of 16:0-fatty acids available for use in glycerolipid synthesis.  
Because di-16:0 PA impairs insulin-signaling via dissociation of mTORC2, concluding 
that only PA, but not DAG, impairs insulin signaling excludes the possibility that the acyl 
chain composition of the lipid intermediate is important for its signaling properties.  
Consistent with the role of acyl chain composition in affecting the potency of lipid 
intermediates, in vitro activation of PKC isozymes varies in response to different DAG 
species (57).  Notably, the high-fat/high-safflower oil diet contains a large proportion of 
18:2 fatty acids and thus a smaller portion of 16:0 fatty acids would be available.  
Therefore, it is possible that DAG containing unsaturated FA are more potent activators 
of PKCε and that PA containing saturated FA are potent activators of mTORC2, 
suggesting that hepatic insulin signaling may be modulated by different lipid 
intermediates in an acyl chain composition-dependent manner.   
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Table 2.3: Summary of GPAT-derived signaling intermediates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lipid droplet metabolism and GPAT 	  
Lipid droplets containing TAG and cholesterol-esters stores can be found in 
virtually all tissues.  A complete review of lipid droplet biogenesis has been published 
elsewhere (58,59).  Under conditions of calorie surplus, tissues such as liver, brown 
adipose, and white adipose accumulate large lipid droplets.  Lipid droplet proteomics 
show that all of the necessary TAG synthetic enzymes, including GPAT4, are present 
on the membrane of lipid droplets (37).   Unlike that of the endoplasmic reticulum, the 
outer coat of lipid droplets is a phospholipid monolayer, requiring that each of the active 
proteins found on the LD surface possess a monolayer-integrating domain.  Upon 
oleate loading, GPAT4 moves from the ER onto the outer layer of the growing lipid 
Isoform Lipid Intermediate Affected Pathway Function 
GPAT1 LPA 
 
 
 
PA, specifically di-
16:0 PA 
 
 
 
 
 
DAG 
Mitochondrial 
fusion (mechanism 
unknown) 
 
When increased in 
primary mouse 
hepatocytes, 
dissociates 
mTORC2/rictor 
association  
 
When increased in 
mouse liver 
activates PKCε 
and inhibits 
phosphorylation of 
IRS1/2 
Impaired 
mitochondrial 
fusion 
 
Inhibits insulin 
signaling 
 
 
 
 
 
Inhibits insulin-
signaling 
GPAT2 Not investigated   
GPAT3 unclear When activity is 
increased activates 
mTORC-
dependent 
phosphorylation of 
p70S6K 
Proposed to 
stimulate growth 
(unconfirmed) 
GPAT4 PA, specifically di-
16:0 PA 
When increased in 
primary mouse 
hepatocytes, 
dissociates 
mTORC2/rictor 
association 
Inhibits insulin 
signaling 
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droplet and this movement results in the accumulation of large lipid droplets (37).  In the 
absence of GPAT4, lipid droplets are sparse.  Interestingly, when mitochondrial GPAT1 
is overexpressed in GPAT4-deficient Drosophila cells numerous small lipid droplets are 
present (37).   These data suggest two key points regarding lipid droplet biogenesis.  
First, in non-adipocytes, lipid droplets do not grow by fusion of smaller droplets, but 
potentially by the synthesis of TAG on the LD surface.  Second, LD size and number 
depends on which GPAT isoform initiates TAG synthesis and not just on the total GPAT 
activity in the tissue.  Further studies are required to determine whether differences in 
LD number and size result in distinct metabolic consequences. 
 
Therapeutic potential of pharmacological inhibition of GPAT 	  
 Based on the known role of GPAT and lipid metabolic enzymes in energy 
homeostasis and insulin resistance, a great deal of interest surrounds their potential as 
therapeutic targets for the treatment of obesity and fatty liver disease (60,61).  However, 
attempts to treat metabolic disease by pharmacological inhibition of GPAT or other 
metabolic enzymes have had limited success.  Partial efficacy in reducing TAG 
absorption has been achieved with Orlistat, through inhibiting the action of pancreatic 
lipase (62).  The predominant side effect is an increase in fecal TAG excretion, making 
its long-term use unpleasant (62).  Because Orlistat does not alter systemic energy 
metabolism, this treatment is ineffective at reducing weight in those individuals 
consuming high-carbohydrate diets.     
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Despite the lack of obvious success stories, some progress has been made with 
regard to the design and synthesis of chemical inhibitors of GPAT activity.  The 
fundamental design of compounds is focused on structures that mimic the phosphate 
group of glycerol-3-phosphate and possess a long saturated chain similar to that of an 
acyl-CoA (63,64) (Fig 2.5).  This work identified 2-(nonylsulfonamido)benzoic acid as 
possessing potent GPAT inhibitory activity.  The structure-activity relationship, a 
description of the specific chemical properties required for inhibitory activity, reveals that 
medium to long-chain alkyl sulfonamide modifications are necessary for activity.  All 
reported modifications or replacements of the benzoic acid ring decreased inhibitory 
activity.  Based on their occlusion from the GPAT active site, a subsequent study 
excluded a class of compounds that substituted the benzoic acid ring for racemic 
cyclopentane and cyclohexane carboxylic acids (64).  The compound with the most 
GPAT inhibitory activity demonstrates an IC50 = 24.7 µM, meaning that 50% of the in 
vitro GPAT activity was inhibited by a compound concentration of 24.7 µM.  
	  
Figure 2.5: Class of compounds possessing GPAT inhibitory activity.  Compounds 
must contain at least 1 benzoic acid ring, and substitutions at R1 and R2 must be polar.  
Substitutions at R3 are required to possess a sulfonamide group with an acyl chain that 
can vary in length.  These compounds are designed to mimic the phosphate group of 
glycerol-3-phosphate and the acyl chain of an acyl-CoA. 	  
As a proof of concept, this compound (renamed FSG67) was used in cellular and 
mouse models (65).  When differentiated 3T3L1 adipocytes were treated with FSG67, 
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TAG accumulation was inhibited in a dose-dependent manner, and at concentrations as 
high as 150 µM, no toxicity was observed.  Intraperitoneal injection of lean or diet-
induced obese mice with 5 or 20 mg/kg FSG67, before the onset of the dark cycle, 
resulted in a ~4% weight loss.  Because this weight loss was paired with reduced 
intake, the authors concluded that FSG67 possesses potent appetite-suppressing 
activity.  Although many drugs possess appetite-suppressing effects, chronic dosing of 
5 mg/kg FSG67 did not impair conditioned taste aversion while still resulting in weight 
loss, suggesting that the decreased food intake was not due to food avoidance.  
Metabolic analysis of FSG67-treated mice revealed reversible weight loss in diet-
induced obese mice after 8 days, resulting primarily from reduced food intake.  Daily 
treatment of DIO mice for 18 days improved glucose tolerance and insulin sensitivity.  
Suggesting that FSG67 regulated central satiety, intracerebroventricular administration 
produced similar effects on weight loss and food intake.   
 
The results from these studies provide some suggestion that pharmacological 
inhibition of GPAT activity is a viable strategy for the treatment of obesity.  However, 
this approach may be problematic. FSG67-dependent hypophagia is transient, 
suggesting that the long-term, weight loss benefits would be limited.  Second, the GPAT 
inhibitory activity of FSG67 exhibited no GPAT isoform selectivity.  Based on the diverse 
functions of the different GPAT isoforms, long-term inhibition of all GPAT activity is likely 
to produce serious side effects.  Although existing GPAT-null mice are viable, these 
models are only evaluating the absence of a single GPAT isoform, and it is unclear 
whether the loss of multiple GPAT isoforms simultaneously would be compatible with 
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life.  Clearly, improving our understanding of the distinct roles of each GPAT isoform will 
provide valuable information in the search for improved therapies for obesity.   
  
Lipodystrophies and Glycerolipid Signals  	  
 Lipodystrophies are a cluster of disorders characterized by impaired adipose 
tissue development or progressive loss of adipose tissue.  Lipodystrophies are divided 
into three major categories: congenital generalized (CGL), familial partial (FPL), and 
acquired (66). Acquired lipodystrophies are most common in individuals undergoing 
anti-retroviral therapy, affecting nearly 100,000 patients in the US (66,67).  Loss of 
adipose tissue in patients with acquired lipodystrophies is highly variable.  The inherited 
lipodystrophies, CGL and FPL, are rare genetic disorders characterized by selective 
and variable lack of adipose tissue (68).  Often diagnosed in the neonatal period, 
children with CGL have accelerated growth rates and uncontrolled appetites (68).  The 
lack of functional adipose tissue for storage of TAG, results in ectopic TAG 
accumulation in the liver and, if untreated, can lead to cirrhosis (68).  Some patients 
present with enlarged hearts and mild mental retardation.  Although several loci remain 
unidentified, recent advances have led to the identification of eight genetic loci linked to 
CGL (68). Patients with type 2 CGL present with the most severe symptoms, most likely 
due to the absence of both metabolic and structural adipose tissue (69).  Although the 
underlying mechanisms in the development of lipodystrophies remain obscure, recent 
studies have revealed a link between CGL and glycerolipid synthesis (70). 
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 Type 2 CGL is caused by loss-of-function mutations in Berardinelli-Seip 
Congenital Lipodystrophy 2 (BSCL2), the gene encoding for the protein Seipin.  
Because Seipin does not posses any known functional domains, it is unlikely that Seipin 
acts as an enzyme in TAG synthesis.  Although its function has yet to be fully described, 
initial reports have identified a role for Seipin in lipid droplet biogenesis (71).  Seipin is 
an endoplasmic reticulum membrane protein, and its mRNA expression is highly 
upregulated with adipocyte differentiation (72); the loss of Seipin is associated with 
increased intracellular PA levels (73,74).  Because of the known role for PA in 
intracellular signaling, it has been suggested that the increased PA acts as negative 
regulator of adipogenesis by inhibiting the master regulator of adipocyte differentiation, 
peroxisome-proliferator activated receptor isoform γ (PPARγ) (75).  PPARγ is a nuclear 
receptor that, in tandem with another transcription factor C/EBPβ, plays a vital role in 
the differentiation of preadipocytes to mature adipocytes (76).  During this transition, 
PPARγ upregulates a host of genes involved with lipid uptake and storage.  
Unsurprisingly, one of the 5 types of familial partial lipodystrophy is caused by PPARγ 
deficiency (66). PPARγ activity can by modified by a number of ligands including the 
thiazolidinedione class of antidiabetic drugs and naturally occurring lipids (76).  Some of 
these lipid species are intermediates in glycerolipid synthesis.  In Chinese hamster 
ovary cells, the overexpression of GPAT1 increased intracellular LPA levels and 
stimulated PPARγ activation (77).  Conversely, overexpression of AGPAT2 increased 
intracellular PA levels and was a potent inhibitor of PPARγ activation (77).  Thus, the 
increased intracellular PA in CGL tissues, the potential for PA to act as an antagonist of 
PPARγ, and the role for GPAT in modulating intracellular PA levels strongly suggests a 
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role for GPAT in CGL.  Our current hypothesis is that during differentiation, Seipin 
regulates GPAT activity and controls intracellular PA levels (Fig 2.6). 
	  
Figure 2.6: Hypothesis for relationship between Seipin, GPAT, and adipogenesis.  
When Seipin is present, GPAT activity and intracellular PA levels are normal, and 
PPARγ can be activated to initiate adipogenesis.  When Seipin is absent, GPAT activity 
and PA levels are increased, thereby inhibiting PPARγ activity and adipocyte 
differentiation.  ER, endoplasmic reticulum; PA, phosphatidic acid. 
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CHAPTER III: GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (GPAT)-1, BUT 
NOT GPAT4, INCORPORATES NEWLY SYNTHESIZED FATTY ACIDS INTO 
TRIACYLGLYCEROL AND DIMINISHES FATTY ACID OXIDATION1 	  
Capsule 
 
Background: The independent functions of the glycerol-3-phosphate acyltransferase 
(GPAT) isoforms are unknown. 
Results: Compared to Gpat4-/-, Gpat1-/- hepatocytes oxidized more fatty acids (FA) and 
were unable to incorporate de novo synthesized FA into triacylglycerol.  
Conclusion: GPAT1, but not GPAT4, metabolizes FA synthesized de novo from 
[14C]acetate and diverts FA away from mitochondrial oxidation. 
Significance: GPAT1 and GPAT4 use different cellular pools of FA. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This chapter previously appeared in an article in the Journal of Biological Chemistry.  The original 
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Summary 	  
Four glycerol-3-phosphate acyltransferase (GPAT) isoforms, each encoded by a 
separate gene, catalyze the initial step in glycerolipid synthesis; in liver, the major 
isoforms are GPAT1 and GPAT4.  To determine whether each of these hepatic isoforms 
performs a unique function in the metabolism of fatty acid, we measured the 
incorporation of de novo synthesized fatty acid or exogenous fatty acid into complex 
lipids in primary mouse hepatocytes from control, Gpat1-/- and Gpat4-/- mice.  Although 
hepatocytes from each genotype incorporated a similar amount of exogenous fatty acid 
into TAG, only control and Gpat4-/- hepatocytes were able to incorporate de novo 
synthesized fatty acid into TAG.  Compared to controls, Gpat1-/- hepatocytes oxidized 
twice as much exogenous fatty acid.  To confirm these findings and to assess hepatic β-
oxidation metabolites, we measured acylcarnitines in liver from mice after a 24 h fast 
and after a 24 h fast followed by 48 h of refeeding with a high sucrose diet to promote 
lipogenesis.  Confirming the in vitro findings, the hepatic content of long-chain 
acylcarnitine in fasted Gpat1-/- mice was 3-fold higher than in controls. Compared to 
control and Gpat4-/- mice, after the fasting-refeeding protocol, Gpat1-/- hepatic TAG was 
depleted and long-chain acylcarnitine content was 3.5-fold higher.  Taken together, 
these data demonstrate that GPAT1, but not GPAT4, is required to incorporate de novo 
synthesized fatty acids into TAG and to divert them away from oxidation. 
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Introduction 	  
Glycerol-3-phosphate acyltransferase (GPAT; EC 2.3.1.15) initiates the pathway 
of TAG synthesis by esterifying a long-chain fatty acyl-CoA to a glycerol-3-phosphate 
backbone at the sn-1 position to form sn-1-acylglycerol-3-phosphate (lysophosphatidic 
acid) (28).  A second esterification at the sn-2 position, is catalyzed by acylglycerol-3-
phosphate acyltransferase.  The phosphate is then hydrolyzed by phosphatidic acid 
phosphohydrolase (lipin), and then a final acylation is catalyzed by diacylglycerol 
acyltransferase to form TAG.  In addition to their roles in TAG synthesis, the 
phosphatidic acid and diacylglycerol intermediates in this pathway are precursors for all 
the glycerophospholipids, and they initiate signaling pathways.   
 
The pathway of TAG biosynthesis is remarkable for the number of isoenzymes 
that catalyze each step.  For example, four independent GPAT isoforms, each encoded 
by a separate gene, catalyze the formation of lysophosphatidic acid, but it is unclear 
why GPAT enzyme redundancy is required.  Studies of mice with deleted GPATs show 
that the isoforms present in liver include primarily GPAT1 (78)  and GPAT4 (12,22), with 
lower expression of GPAT2 (79) and GPAT3 (10).  Each of the GPAT isoforms is an 
intrinsic membrane protein whose active site faces the cytosol (19).  GPAT1, located on 
the outer mitochondrial membrane and at contact sites with the endoplasmic reticulum 
(80), has a strong preference for saturated fatty acids (28).  GPAT1 comprises 30-50% 
of total activity in liver (28), and Gpat1 mRNA expression is highly responsive to 
SREBP1c and is upregulated when dietary carbohydrate intake and circulating insulin 
concentrations are high (81).  Absent GPAT1 protects against the development of 
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hepatic steatosis caused by a high fat diet (5) or by the upregulation of SREBP1c in 
ob/ob mice (32).  Conversely, GPAT1 overexpression causes hepatic steatosis (48) and 
insulin resistance (39).  GPAT4, which is located on the endoplasmic reticulum and on 
lipid droplets (37), contributes 40-50% of total hepatic GPAT activity (12).  Like GPAT1, 
GPAT4 also appears to be important for hepatic TAG synthesis, because the TAG 
content in Gpat4-/- liver is 42% lower than in control mice (12).  
 
Hepatic triacylglycerol synthesis is enhanced by the increased availability of long-
chain fatty acids synthesized within hepatocytes from dietary glucose, or from fatty acid 
that enters hepatocytes exogenously from dietary chylomicron remnants or as free fatty 
acids lipolyzed from adipose tissue.  Because SREBP1c concomitantly upregulates 
both GPAT1 and the enzymes that catalyze the de novo synthesis of fatty acids, 
including acetyl-CoA carboxylase and fatty acid synthase (82), we hypothesized that the 
function of GPAT1 and de novo lipogenesis might be intrinsically linked.  To test this 
hypothesis, we compared the ability of GPAT1 and GPAT4 to use exogenous versus de 
novo synthesized fatty acids in control and knockout mice and in their hepatocytes.   
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Experimental Procedures 	  
Materials 
Type I collagenase was from Worthington Biochemical Corporation.  [1-14C]acetic 
acid and [1-14C]palmitic acid were purchased from PerkinElmer Life Sciences.  Silica G 
gel plates were from Whatman.  Tissue culture plates were from BD Biosciences, and 
media were obtained from Invitrogen.  Sigma was the source of 4-methylene-2-octyl-5-
oxotetrahydrofuran-3-carboxylic acid (C75) and all other chemicals, unless otherwise 
indicated. 
 
Animal care and hepatocyte isolation 
Animal protocols were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee.  Mice were housed in a pathogen-free 
barrier facility on a 12-h light/dark cycle with free access to water and food (Prolab 5P76 
Isopro 3000; 5.4% fat by weight).  Gpat1-/- (5) and Gpat4-/- (12,13) mice had been 
backcrossed at least eight times onto a C57BL6/J background.  At 8 weeks of age, 
littermate controls, and Gpat1-/-, and Gpat4-/- mice were either fasted for 24 h or fasted 
for 24 h and then refed a high sucrose diet for 48 h before sacrifice.  The high sucrose 
diet was modified from Research Diets D12450B (10% kcal fat, 20% kcal protein and 
70% kcal carbohydrate (525 g/kg sucrose, 175 g/kg corn starch)). 
 
To isolate hepatocytes, after mice were anesthetized with 250 mg/kg Avertin, a 
22G catheter was inserted into the vena cava, and the liver was perfused with wash 
buffer (10 mM Hepes, 132 mM NaCl, 6.7 mM KCl, 20 mM glucose, 0.5 M adenosine, 
	  	   32	  
100 mM EGTA, 140 nM insulin, pH7.4), and then with digestion buffer (100 mM HEPES, 
57 mM NaCl, 6.7 mM KCl, 5 mM CaCl2, 20 mM glucose, 0.45 mg/ml type 1 
collagenase, pH 7.4).  The digested liver was removed and placed in a 100 mm dish on 
ice with Hanks/BSA buffer (10 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 1.26 mM CaCl2, 
0.8 mM MgSO4, 4.2 mM NaHCO3, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 5 mM 
glucose, pH7.4).  The hepatocytes were dissociated and filtered through a cell strainer, 
centrifuged at 4°C at 50 × g for 3 min, then washed once in Williams’ medium E.  The 
cells were re-suspended in Williams’ Medium E:Percoll (16 ml:14 ml), centrifuged at 4°C 
at 400 × g for 8 min, and washed with Williams’ medium E.  Cells were plated onto 60 
mm collagen-coated dishes and incubated for 90 min in Williams’ medium E + 10% 
FBS.  After the cells attached, the medium was changed to Williams’ medium E, 100 U 
penicillin/streptomycin, 50 nM insulin, 0.1 µM dexamethasone, and 0.1% BSA. 
     
GPAT Activity 
Hepatocytes were cultured overnight in 60 mm plates, then scraped and 
homogenized in cold Medium I (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 
mM dithiothreitol) with 10 up-and-down strokes with a Teflon-glass motor-driven 
homogenizer.  Liver was minced, then homogenized similarly.  Total membranes were 
isolated by centrifuging the homogenate at 100,000 x g for 1 h.  GPAT specific activity 
was assayed for 10 min at room temperature in a 200 µl reaction mixture containing 75 
mM Tris-HCl, pH 7.5, 4 mM MgCl2, 1 mg/ml BSA (essentially fatty acid–free), 1 mM 
dithiothreitol, 8 mM NaF, 800 µM [3H]glycerol 3-phosphate, and 80 µM palmitoyl-CoA 
(80). The reaction was initiated by adding 10-30 µg of membrane protein after 
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incubating the membrane protein on ice for 15 min in the presence or absence of 2 mM 
N-ethylmaleimide (NEM), which inactivates GPAT isoforms 2, 3, and 4. The reaction 
products were extracted into CHCl3, dried under N2, resuspended in 4 mLs Cytoscint 
and counted on scintillation counter.  NEM-resistant activity (GPAT1) was calculated by 
subtracting NEM-sensitive activity from total activity.   
 
RNA extraction and RT-PCR 
Total RNA was extracted from overnight cultures of hepatocytes with TRIzol 
(Invitrogen).  cDNA synthesis and real time RT-PCR were performed as described (83).  
Primer sequences for each GPAT isoform and data normalization used were described 
(52,83).   
 
Labeling, Oxidation, and Lipid Extraction 
Sixteen to 20 h after plating, hepatocytes were labeled with 0.5 ml of labeling 
buffer (Krebs Ringer buffer, 10 mM HEPES, 5.5 mM glucose, 0.25% fatty acid-free 
bovine serum albumin (BSA), and 1 mM carnitine) containing 500 µM  [1-14C]acetic acid 
or [1-14C]palmitic acid for 2 h.  Media were removed, and CO2 was liberated by adding 
100 µl 70% perchloric acid, and trapped in 1M NaOH.  An aliquot of the NaOH was 
counted to measure radiolabeled CO2.  To quantify intracellular oxidation metabolites, 
fresh Krebs Ringer buffer and 100 µL 70% perchloric acid were added to each plate and 
acidified supernatants were collected. The acidified media and cell supernatants were 
incubated overnight with BSA and then centrifuged at 14,000 x g for 20 min.  Aliquots of 
the supernatant were counted to measure radiolabeled acid soluble metabolites (ASM), 
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a measure of incomplete fatty acid oxidation. Cells were washed with 1% BSA and then 
with phosphate buffered saline before lipids were extracted (84).  Lipid extracts and 
standards were separated by thin layer chromatography on Partisil LK5D Silica gel 
plates in a two-phase system: chloroform: methanol: ammonium hydroxide (65:25:4, 
v/v/v) run to 50% of the plate, then dried and followed by heptane: isopropyl ether: 
acetic acid (60:40:4, v/v/v) run to the top of the plate.  Radiolabeled lipids were 
quantified with a Bioscan AR-2000 Imaging Scanner.  Lipid standards were visualized 
by iodine staining.  
 
Blood Chemistries and Lipids 
Before blood collection, mice were either fasted for 24 h or fasted 24 h and then 
fed a high sucrose diet for 48 h. Plasma TAG (Stanbio, Boerne, TX), free fatty acid 
(Wako Diagnostics, Richmond, VA), glucose (Glucose CII, Wako Diagnostics), and b-
hydroxybutyrate (Wako Diagnostics) were determined by enzymatic colorimetric 
methods.  
 
Lipid Extraction and TAG Measurement in Liver 
Liver lipids were extracted (39), dried under N2 gas, resuspended in 200 µL tert-
butanol:methanol:TritonX-100 (3:1:1, v/v), and analyzed colorimetrically as described 
above. 
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Liver Acylcarnitine Measurement 
Livers were snap-frozen in liquid nitrogen, pulverized, and weighed.  The 
pulverized liver (50-100 mg) was homogenized in acetonitrile:water:formic acid 
(50:49.7:0.3; v/v) at a final concentration of 50 mg/ml.  Acyl-carnitines, were analyzed 
by flow injection tandem mass spectrometry (85).  Samples were stored at -80 oC 
before analysis.   
 
Statistics 
Data represent means ± SEM of at least three independent experiments 
performed in triplicate unless indicated otherwise. In vitro models were analyzed by 1-
way ANOVA comparing each genotype versus controls, and post-hoc comparisons of 
diet conditions within each genotype. Data were considered significant at P<0.05. 
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Results 	  
Isolated and cultured primary hepatocytes retained GPAT specific activity. 
In order to compare the contributions of GPAT1 and GPAT4 to the total amount 
of GPAT activity, we isolated and cultured primary hepatocytes from control, Gpat1-/- 
and Gpat4-/- mice and measured GPAT specific activity in the presence and absence of 
NEM, which inhibits GPAT2, 3, and 4 (Fig 3.1A). Compared to wild type hepatocytes, 
total GPAT specific activity in Gpat1-/- hepatocytes was 35% lower and minimal residual 
NEM-resistant GPAT activity remained, whereas NEM-sensitive GPAT activity was 
unchanged.  Total GPAT specific activity in Gpat4-/- hepatocytes was 42% lower than in 
control hepatocytes; NEM-resistant GPAT specific activity was unchanged, but NEM-
sensitive GPAT activity was 60% lower.  The residual NEM-sensitive GPAT activity is 
likely due to GPAT2 and 3.  These results show that isolated and cultured primary 
hepatocytes retained GPAT activity and that the specific activity was similar in Gpat1-/- 
and Gpat4-/- hepatocytes. 
 
To determine whether other GPAT isoforms were affected by deletion of either 
GPAT1 or GPAT4, we measured mRNA expression of each GPAT isoform (Fig 3.1B).  
In Gpat1-/- hepatocytes GPAT3 mRNA abundance was 2-fold higher than in wild type 
hepatocytes, but NEM-sensitive GPAT activity did not change, indicating a lack of 
compensation.  In the absence of GPAT4, the mRNA expression of GPAT2 and 3 
increased 2.5- and 3.5-fold, respectively. GPAT2 activity is extremely low in liver (79), 
and even when the amount of GPAT2 mRNA doubles, probably does not contribute 
substantially to total NEM-sensitive GPAT activity.  However, we cannot differentiate 
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between GPAT3 and GPAT4 protein or activity, so the 42% lower NEM-sensitive GPAT 
activity (Fig. 1B) may reflect partial compensation by GPAT3. 
 
The incorporation of de novo synthesized fatty acid into TAG required GPAT1 
Because GPAT1 is upregulated by SREBP1c, we hypothesized that it might be 
functionally and specifically linked to de novo lipogenesis, such that newly synthesized 
fatty acids would be incorporated into TAG.  Using [1-14C]acetate, we measured the 
ability of control, Gpat1-/- and Gpat4-/- hepatocytes to incorporate de novo synthesized 
fatty acid into TAG and PL.  The incorporation of acetate into TAG and PL was equal in 
hepatocytes from wild type and Gpat4-/- mice, however in Gpat1-/- hepatocytes, the 
incorporation of [14C]acetate into PL was 78% lower than in controls, and the 
incorporation into TAG was virtually absent (Fig 3.2A,B).  When wild type and Gpat4-/- 
hepatocytes were cultured in the presence of the fatty acid synthase inhibitor C75, 
[14C]acetate incorporation into TAG was inhibited 80-85% (Fig 3.2A).  However, in 
Gpat1-/- hepatocytes, C75 had no additional effect, indicating that the absence of 
GPAT1 in hepatocytes had abolished the incorporation of the de novo synthesized fatty 
acid.  In wild type and Gpat4-/- hepatocytes, C75 decreased acetate incorporation into 
PL by 60%, but only by 27% in Gpat1-/- hepatocytes (Fig 3.2B).  In each group of 
hepatocytes, the addition of C75 decreased the incorporation of acetate into free fatty 
acids by more than 72% (data not shown).  These results show that GPAT1, but not 
GPAT4, is required to incorporate de novo synthesized FA into complex lipids.   
 
	  	   38	  
Both GPAT1 and GPAT4 can incorporate exogenous fatty acids into TAG and 
phospholipid 
In addition to de novo synthesis, liver fatty acids are also derived from 
exogenous sources.  To distinguish between the functions of GPAT1 and GPAT4 in the 
use of exogenous fatty acids, we measured the incorporation of [1-14C]palmitate into 
glycerolipids in primary hepatocytes.  In contrast to fatty acids derived from de novo 
synthesis, the incorporation of [1-14C]palmitate into TAG and PL was not altered by the 
absence of either GPAT1 or GPAT4 (Fig 3.3A,B), indicating that neither isoform was 
essential for use of exogenous fatty acid.  Thus, in both Gpat4-/- or Gpat1-/- hepatocytes, 
the remaining GPAT isoforms can fully incorporate exogenous fatty acid into 
glycerolipids. 
 
In hepatocytes, the absence of GPAT1, but not GPAT4, increased fatty acid oxidation  
Previous studies have strongly suggested that GPAT1 competes with CPT1 for 
acyl-CoAs at the outer mitochondrial membrane (39).  To confirm this competition for 
acyl-CoAs and to determine whether GPAT4 located on the endoplasmic reticulum 
competes similarly, we measured the incorporation of [1-14C]palmitate into ASM, a 
measure of incomplete fatty acid oxidation.  Gpat1-/- hepatocytes oxidized [14C]palmitate 
at a rate 200% higher than control hepatocytes, but the incorporation of [14C]palmitate 
into ASM by Gpat4-/- hepatocytes was unchanged (Fig 3.3C).  Of the total ASM 
extracted from the media and cells, intracellular ASM comprises only 5% of the total 
ASM (see inset Fig 3.3C); thus, media ASM reflects 95% of the total ASM produced.  
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These data show that only GPAT1 competes with CPT1 for acyl-CoAs, thereby 
diminishing the flux of fatty acid into the mitochondria for oxidation.  
 
Hepatic GPAT1 diminished fatty acid transport into mitochondria in vivo.  
To confirm the disparate effects of each GPAT isoform on the β-oxidation of 
exogenous versus de novo synthesized fatty acid in vivo, we measured hepatic 
acylcarnitine content in wild type, Gpat1-/- and Gpat4-/- mice after food was removed for 
24 h.  Because fasting increases the flux of adipose-derived fatty acids into the liver, 
more fatty acids are transported to the mitochondria via CPT1, thereby elevating the 
content of hepatic long-chain acylcarnitines. These metabolites are subsequently 
reconverted to acyl-CoAs in the mitochondrial matrix, where they enter the β-oxidation 
pathway.  In fasting mice of each genotype, the content of free carnitine (C0), 
acetylcarnitine (C2), short-chain (C3-C6), and medium-chain (C8-C12) acylcarnitine 
species was similar (Fig 3.4A,C).  Consistent with the hypothesized ability of GPAT1 to 
compete with CPT1 for acyl-CoAs, total long-chain (C14-C22) acylcarnitine content in 
fasted Gpat1-/- liver was 3-fold higher than in control liver (Fig 3.4C).  The most 
abundant long-chain acylcarnitine species, 14:0, 16:1, 16:0, 18:2, 18:1 and 18:0, were 
2- to 6-fold higher than in control liver (Fig 3.4E).  In contrast, and consistent with the in 
vitro data, the acylcarnitine content in livers of fasted Gpat4-/- mice was similar to that of 
control mice.   
 
Because GPAT1 was essential for the incorporation of de novo synthesized fatty 
acids into complex lipids in vitro, we predicted that the absence of hepatic GPAT1 in 
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vivo would also increase the transport of de novo synthesized fatty acids into 
mitochondria.  To test this hypothesis, we fasted mice for 24 h, then refed with a high 
sucrose diet for 48 h to stimulate de novo lipogenesis.  The total long-chain (C14-C22) 
acylcarnitine content of Gpat1-/- liver remained 3.5-fold higher than that of controls, and 
the most abundant long-chain acylcarnitine species, 14:0, 16:1, 16:0, 18:2, 18:1 and 
18:0, ranged from 2- to 5-fold higher (Fig 3.4D,F).  In contrast, no differences were 
observed in the hepatic acylcarnitine content of Gpat4-/- mice that had been fasted and 
then refed (Fig 3.4B,D,F). Thus, GPAT1, but not GPAT4, was required in vivo to 
diminish CPT1-mediated transport of both de novo synthesized and exogenous fatty 
acid. 
 
Hepatic GPAT1 was essential for the incorporation of de novo synthesized fatty acid 
into TAG. 
Because the absence of GPAT1 increased hepatic β-oxidation of de novo 
synthesized fatty acids in vivo, we predicted that the liver TAG content would be low.  
After a 24 h fast, hepatic TAG content in control, Gpat4-/- and Gpat1-/- liver was similar.  
After refeeding a high sucrose diet to enhance de novo lipogenesis, the TAG content in 
control and Gpat4-/- liver increased 2- to 2.5-fold (Fig 3.5A), however, the hepatic TAG 
content of Gpat1-/- liver did not increase.  These data support the conclusion that 
GPAT1 is essential for the incorporation of de novo synthesized fatty acid into TAG and 
for diverting those fatty acids away from mitochondrial oxidation.  
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The absence of GPAT1, but not GPAT4, increased ketogenesis during fasting. 
When the concentration of plasma glucose decreases during an extended fast, 
adipocyte-derived fatty acids flood into the liver, their oxidation rate increases, and 
ketone bodies are synthesized and secreted into the blood.  The accumulation of long-
chain acylcarnitines in the liver and an elevated plasma concentration of ketone bodies 
suggests an increased rate of hepatic fatty acid oxidation.  Because, GPAT1 diminishes 
the oxidation of exogenous fatty acid in vitro and the absence of GPAT1 in liver results 
in the accumulation acylcarnitines, we predicted that fasting would result in a higher rate 
of hepatic β-oxidation in Gpat1-/- mice than in controls.  To confirm this hypothesis we 
measured plasma ketone bodies in control, Gpat1-/- and Gpat4-/- mice.  After a 24 h fast, 
the concentrations of plasma glucose and TAG in control and Gpat1-/- mice were similar 
(Fig 3.5B,C), but plasma fatty acid concentration in Gpat1-/- mice was elevated 1.5-fold 
compared to controls (Fig 3.5D). Consistent with elevated fatty acid oxidation in Gpat1-/- 
mice, plasma β-hydroxybutyrate concentration was 2-fold higher than controls (Fig 
3.5E).  
 
Ketogenesis remained elevated in Gpat1-/- mice during refeeding. 
After a 24 h fast, refeeding with high sucrose drives hepatic de novo lipogenesis, 
promotes TAG storage, and blocks fatty acid oxidation (86).  Because our data 
suggested that GPAT1 esterifies de novo synthesized fatty acids, we asked whether the 
rate of hepatic fatty acid oxidation would remain elevated during short-term high 
sucrose refeeding.  Consistent with a higher rate of hepatic fatty acid oxidation in the 
absence of GPAT1, the plasma β-hydroxybutyrate concentration in Gpat1-/- mice was 3-
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fold higher than in control or Gpat4-/- mice (Fig 3.5D).  Consistent with diminished 
hepatic TAG synthesis in both Gpat1 and Gpat4 null mice, compared to controls, the 
plasma TAG concentration was 48% lower in Gpat1-/- mice and 25% lower in Gpat4-/- 
mice (Fig 3.5C).  Plasma glucose and fatty acid concentrations in each genotype were 
similar (Fig 3.5B,E). 
 
 
 
 
 
 
 
 
 
 
  
	  	   43	  
Discussion 	  
With the discovery of 4 independent GPAT isoforms that differ in tissue 
distribution, subcellular location, acyl-CoA preference, and transcriptional regulation, 
questions have arisen as to the specific function of each isoform (28).  Gpat2 mRNA is 
most strongly expressed in testes and probably plays a minor role in liver, but the 
mRNA expression and activities in liver of the remaining GPAT isoforms are high 
(10,28,79,87).  Although studies suggest that GPAT3 is regulated by PPARγ and 
PPARδ in keratinocytes (88) and by insulin-mediated phosphorylation in 3T3-L1 
adipocytes (36), the regulation and specific contributions of hepatic GPAT3 to 
glycerolipid synthesis are unknown.  The availability of Gpat1- and Gpat4- knockout 
mice, however, has allowed us to directly compare them and to delineate the specific 
roles of each isoform. 
 
The function of GPAT1 in the esterification of fatty acids has been best studied.  
GPAT1 esterification rates for 16:0-CoA are 3- to 10-times higher than those observed 
with 18:0-, 18:1-, 18:2n6-, and 18:3n3-CoAs (31,89-91).  Examination of the glycerolipid 
species in Gpat1-/- liver have confirmed the preference of GPAT1 for 16:0-CoA, because 
the absence of GPAT1 results in decreases in the amounts of 16:0 esterified to 
phosphatidylcholine and phosphatidylethanolamine in membranes from total liver (5) 
and from liver mitochondria (7).  The 16:0 deficiencies at the sn-1 position of 
phosphatidylcholine and phosphatidylethanolamine are compensated for by increases 
in the content of 18:1 at the sn-1 position and of 20:4n6 at the sn-2 position.   
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A second function of GPAT1 is related to de novo lipogenesis.  This role is 
implied by the fact that GPAT1’s specific activity is low in liver during fasting, in part 
because of inhibition by AMP-activated kinase (30), and is upregulated transcriptionally 
when lipogenesis from carbohydrate precursors is enhanced.  Similar to acyl-CoA 
carboxylase and fatty acid synthase, Gpat1 mRNA, protein, and specific activity 
increase in response to SREBP1c upregulation, which, in turn, is stimulated by insulin 
and depressed via LXR by polyunsaturated fatty acids (81).  Thus, GPAT1 is markedly 
elevated in ob/ob mice, and a deficiency in ob/ob mice of either Gpat1 itself (32) or of 
SREBP1c (82) protects against the development of a fatty liver.  In addition to 
promoting the synthesis of TAG, indirect evidence suggests that GPAT1 diverts acyl-
CoAs away from CPT1 and β-oxidation, because long-chain acylcarnitines and β-
hydroxybutyrate increase in Gpat1-/- mice fed an obesigenic diet that is high in sucrose 
and palm oil (39).  Thus, under conditions when the synthesis of fatty acid is elevated, 
the presence of GPAT1 would ensure that the resulting fatty acids are esterified rather 
than oxidized.  Our current data directly support this idea. 
 
In isolated hepatocytes, incubation with [14C]acetate showed that only the 
deficiency of GPAT1 blocked the incorporation of de novo synthesized fatty acids into 
glycerolipids.  The incorporation was equivalent in control and Gpat4-/- hepatocytes and 
was diminished equally by the fatty acid synthase inhibitor C75.  These data suggest 
that fatty acids synthesized de novo from glucose require GPAT1 in order to be 
incorporated into TAG.  Perhaps because of GPAT1’s preference for 16:0-CoA, the 
predominant species synthesized de novo by fatty acid synthase, GPAT1 was also 
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responsible for most of the acetate-derived fatty acid that was incorporated into PL.  
Inhibition of fatty acid synthesis by C75 had a weaker effect on PL synthesis than it did 
on TAG synthesis, suggesting that de novo synthesized fatty acids may be preferentially 
directed to TAG storage, consistent with the fact that lipogenesis is upregulated when 
high carbohydrate intake and insulin concentrations activate SREBP1c.  The final step 
in the synthesis of TAG is catalyzed by DGAT1 and DGAT2.  Stable isotope studies 
show that only DGAT2 incorporates fatty acids synthesized de novo (92). 
 
Because Gpat1-/- hepatocytes failed to incorporate label from [14C]acetate into 
TAG, we concluded that GPAT1 is required for the synthesis of TAG from de novo 
lipogenesis.  Confirming this interpretation, after the fast-refeeding protocol to promote 
hepatic de novo lipogenesis, Gpat1-/- liver contained 53% less TAG than did controls.  
Compared to fasted mice, the hepatic TAG content in both refed-control and refed-
Gpat4-/- mice increased 2- and 3-fold, respectively, but liver TAG content in refed-Gpat1-
/- mice did not change, indicating that Gpat1-/- failed to incorporate de novo-derived fatty 
acid into hepatic TAG.  A direct comparison of hepatic β-oxidation revealed that 
compared to controls, long-chain acylcarnitines and β-hydroxybutyrate in Gpat1-/- mice 
were 3.5- and 2-fold higher, respectively.  Thus, when hepatic GPAT1 was absent, the 
de novo synthesized fatty acids were oxidized rather than incorporated into TAG.  
These data are consistent with our in vitro findings and confirm that GPAT1 is required 
to incorporate de novo synthesized fatty acids into TAG and diminish fatty acid 
oxidation.   
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In humans, VLDL secretion is stimulated by dietary sugars, and after a high 
carbohydrate load, de novo synthesized fatty acids comprise roughly 37% of plasma 
VLDL-TAG (93,94).  Consistent with a role for GPAT1 in incorporating de novo 
synthesized fatty acids into VLDL, Gpat1-/- mice fed a diet containing 60% of calories 
from sucrose were protected from hypertriglyceridemia and showed diminished VLDL 
secretion rates (95).  After the fasting-refeeding protocol, plasma TAG concentrations in 
Gpat1-/- mice did not change, suggesting that GPAT1 is essential for the postprandial 
lipemia that is stimulated by carbohydrate feeding.  In contrast, plasma TAG in refed 
control and Gpat4-/- mice increased 2 and 3.5-fold, respectively, consistent with the 
continued presence and function of GPAT1 in using de novo synthesized TAG in VLDL.  
 
The absence of either GPAT1 or GPAT4 did not block the incorporation of 
exogenous fatty acid into TAG or PL.  Normal incorporation seems surprising because 
TAG content in both Gpat1-/- and Gpat4-/- liver is 40-50% lower than controls (5,15).  
However, our hepatocytes studies measured TAG synthesis from [14C]palmitate in the 
absence of insulin.  Normally after a 24 h fast, when insulin levels are low, fatty acids 
released from adipocytes constitute the majority of the fatty acid entering the liver to be 
stored or incorporated into VLDL-TAG, a process that is not sensitive to plasma insulin 
levels (93).  Under these conditions, fatty acids entering the liver might be preferentially 
oxidized for energy, and the remaining low GPAT activity would suffice for a minimal 
demand for TAG synthesis for storage or for VLDL secretion.  Consistent with this idea 
and with our in vitro results, liver TAG content was similar in fasting control, Gpat1-/- and 
Gpat4-/- mice.  After feeding in humans, concomitant with a rise in plasma insulin, both 
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dietary fatty acids and those derived from de novo synthesis are incorporated into TAG 
(93).  Because the TAG content in Gpat1-/- liver was lower than in controls after high 
sucrose refeeding, it is likely that insulin-induced SREBP1c activity drove fatty acid flux 
toward TAG storage; however, in the absence of GPAT1, the remaining GPAT activity 
was unable to meet the demand for higher TAG synthesis.  
 
Because Gpat1-/- mice fed low or high fat diets for 4 months had a higher content 
of plasma and liver acylcarnitines and higher concentrations of plasma β-
hydroxybutyrate, we had speculated that GPAT1 might normally divert fatty acids away 
from CPT1 and β-oxidation (39).  The present results directly support this hypothesis by 
showing that, compared to controls, Gpat1-/- hepatocytes produced twice as much ASM 
from [14C]palmitate and that plasma β-hydroxybutyrate and hepatic acylcarnitines were 
markedly elevated in Gpat1-/- mice under both fasted and refed conditions.  In contrast, 
ASM production was similar in Gpat4-/- and control hepatocytes under both conditions, 
indicating that lack of GPAT4 did not increase the use of excess acyl-CoAs for β-
oxidation.   
 
In order to directly compare β-oxidation metabolites from the two Gpat null 
genotypes, we investigated acylcarnitines.  After a 24 h fast, the hepatic content of long-
chain acylcarnitines was equivalent in control and Gpat4-/- mice.  Confirming the 
hypothesis that GPAT1 competes with CPT1 for acyl-CoAs and diverts them away from 
mitochondria, the content of long-chain acylcarnitines in Gpat1-/- livers was 3-fold higher 
than controls. Thus, despite the observation that exogenous fatty acid incorporation into 
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TAG was unaffected by a deficiency of either GPAT1 or GPAT4, these results further 
support GPAT1’s unique function of diverting fatty acids away from β-oxidation. 
 
These studies clearly differentiate the roles of the major hepatic isoforms, GPAT1 
and GPAT4.  GPAT1, but not GPAT4, reciprocally regulates hepatic de novo 
glycerolipid synthesis and fatty acid oxidation.  In this role, the absence of GPAT1 
protects mice from high fat diet- and genetic- induced hepatic steatosis and hepatic 
insulin resistance (32).  Conversely, the increased expression of GPAT1 may contribute 
to insulin resistance, both by diverting fatty acids away from oxidation and towards 
glycerolipid synthesis and by increasing lipid intermediates like diacylglycerol and 
phosphatidic acid which impair hepatic insulin signaling (48,52).   
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Figures 
	  
Figure 3.1: GPAT specific activity and mRNA expression in primary hepatocytes 
from wild type, Gpat1-/- and Gpat4-/- mice. A) GPAT specific activity was measured in 
total particulate preparations of primary hepatocytes cultured for 16 h; triplicates from 
two independent experiments.  Total, N-Ethylmaleimide-resistant (NEM-R) and sensitive 
(NEM-S) GPAT specific activities are shown.  B) mRNA expression of each GPAT 
isoform was measured by RT-PCR.  Total RNA was obtained from primary hepatocytes 
in triplicate from two experiments. Data are presented as means ± SE. 
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Figure 3.2: Gpat1-/- hepatocytes incorporated less [14C]acetate into glycerolipids.  
Hepatocytes were labeled with 500 µM [1-14C]acetate in the presence or absence of 20 
µg/ml C75 for 2 h.  [1-14C]acetate incorporation into A) triacylglycerol or B) 
phospholipids in control, Gpat1-/-, or Gpat4-/- hepatocytes.  Data show means ± SE of 
two experiments performed in triplicate. 
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Figure 3.3: GPAT1 was not required for the incorporation of exogenous fatty acid, 
however β-oxidation was higher in Gpat1-/- hepatocytes. Hepatocytes from wild 
type, Gpat1-/- (G1-/-) or Gpat4-/- (G4-/-) mice were labeled with 500 µM [1-14C]palmitic 
acid for 2 h.  [1-14C]palmitic acid incorporation into A) triacylglycerol, B) phospholipids 
and  C) ASM.  Data show means ± SE of two experiments performed in triplicate.  D) 
Comparison of cell media and intracellular (IntraC) ASM.  Data show means of one 
experiment performed in quadruplicate. 
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Figure 3.4: Long-chain acylcarnitine content was higher in Gpat1-/- liver than 
controls after a 24 h fast and after 48 h of refeeding. Wild type, Gpat1-/-, and Gpat4-/- 
mice were fasted for 24 h or fasted for 24 h and then refed with a high sucrose diet for 
48 h.  Hepatic content of free carnitine (C0), acetylcarnitine (C2) (A and B).  Short, 
medium and long-chain acylcarnitine content of mouse liver (C and D).  Major hepatic 
long-chain acylcarnitine species from mice (E and F). Data are shown as means ± SE. 
Significant differences are indicated by (*) for genotype and (#) for diet challenge. (P 
<.05, ANOVA) (n=6 diet, genotype). 
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Figure 3.5: Liver and plasma metabolites.  Liver TAG content of wild type, Gpat1-/-, 
and Gpat4-/- mice fasted for 24 h or fasted for 24 h then refed with a high sucrose diet 
for 48 h.  Plasma B) β hydroxybutyrate, C) fatty acid, D) glucose, and E) TAG.  Data are 
shown as means ± SE.  Significant differences are indicated by (*) for genotype and (#) 
for diet challenge. (P <.05, ANOVA) (n=6 diet, genotype). 
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Figure 3.6: GPAT1, but not GPAT4, is required for the incorporation of de novo 
synthesized fatty acids into triacylglycerol and to divert fatty acids away from β-
oxidation. 
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Chapter IV: GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE ISOFORM-4 (GPAT4) 
LIMITS OXIDATION OF EXOGENOUS FATTY ACIDS IN BROWN ADIPOCYTES2	   	  
Capsule 
 
Background: GPAT4 is a major GPAT isoform in brown adipose tissue. 
Results: Compared to control cells, brown adipocytes lacking GPAT4 oxidize 40% 
more exogenous fatty acids. 
Conclusion: GPAT4 in BAT is required to limit oxidation of exogenous fatty acid. 
Significance: The function of each GPAT isoform is tissue-specific and evolved to 
perform a unique function within a physiological context.  
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Summary  
 
Glycerol-3-phosphate acyltransferase-4 (GPAT4) null pups grew poorly during 
the suckling period and, as adults, were protected from high fat diet-induced obesity.  
To determine why Gpat4-/- mice failed to gain weight during these two periods of high-fat 
feeding, we examined energy metabolism.  Compared to controls, the metabolic rate of 
Gpat4-/- mice fed a 45% fat diet was 12% higher.  Core body temperature was 1ºC 
higher after high-fat feeding.  Food intake, fat absorption, and activity were similar in 
both genotypes.  Impaired weight gain in Gpat4-/- mice did not result from increased 
heat loss, because both cold tolerance and response to a β3-adrenergic agonist were 
similar in both genotypes.  Because GPAT4 comprises 65% of the total GPAT activity in 
brown adipose tissue (BAT), we characterized BAT function.  A 45% fat diet increased 
the Gpat4-/- BAT expression of PPARα target genes, Cpt1α, Pgc1α, and Ucp1, and BAT 
mitochondria oxidized oleate and pyruvate at higher rates than controls, suggesting that 
fatty acid signaling and flux through the TCA cycle were enhanced.  To assess the role 
of GPAT4 directly, neonatal BAT preadipocytes were differentiated to adipocytes.  
Compared to controls, Gpat4-/- brown adipocytes incorporated 33% less fatty acid into 
triacylglycerol and 46% more into the pathway of β-oxidation.  The increased oxidation 
rate was due solely to an increase in the oxidation of exogenous fatty acids.  These 
data suggest that in the absence of cold exposure, GPAT4 limits excessive fatty acid 
oxidation and the detrimental induction of a hypermetabolic state. 
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Introduction 
Glycerol-3-phosphate acyltransferase (GPAT; EC 2.3.1.15) catalyzes the 
esterification of long-chain acyl-CoAs at the sn-1 position of glycerol-3-P and is the 
initial and rate limiting step for the synthesis of triacylglycerol (TAG) and all the 
glycerophospholipids.  Four mammalian GPAT isoforms, each the product of a separate 
gene, have been identified, and the phenotypes differ in mice deficient in GPAT1, -3, 
and -4.  Lack of GPAT1 results in lower hepatic TAG content with less palmitate in the 
sn-1 position of phosphatidylcholine and phosphatidylethanolamine, resistance to high 
fat diet (HFD)–induced insulin resistance (5,6), increased hepatic fatty acid oxidation 
(6), and resistance to diethylnitrosamine-induced hepatocellular carcinoma  (8). GPAT3 
contributes nearly 80% of total GPAT activity in white adipose tissue, but GPAT3 
deficient mice are not lipodystrophic and gain weight normally when fed a high fat diet 
(10,11).  A mouse deficient in GPAT2 has not been reported, and recent data suggest 
that GPAT2 may esterify both glycerol-3-P and lysoglycerol-3-P in testis (9).  Many of 
the phenotypic differences in GPAT-null animals are likely due to variation in nutritional 
regulation and tissue-dependent expression of each GPAT isoform.   
 
Previously called acylglycerol-3-phosphate acyltransferase isoform 6 (AGPAT6) 
because of its similarity to AGPAT1 and -2, GPAT4 has 66 % amino acid identity to 
GPAT3 and does not possess AGPAT activity (15).  GPAT4 is a major GPAT isoform in 
liver (12) and is highly expressed in the mammary gland where it is required for 
development and for the deposition of diacylglycerol and TAG in milk (13).  In Gpat4-/- 
liver, compared to controls, total GPAT specific activity and TAG content are 45% lower 
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(14,15).  Mice deficient in GPAT4 are protected from diet and genetically induced 
obesity, and, compared to controls, their metabolic rate was reported to be 5% higher 
(5).  This metabolic phenotype had been attributed to the absence of a subdermal 
adipose layer at 12 weeks of age (15).  However, it is unclear whether the lack of 
subdermal adipose in Gpat4-/- mice is the cause of or an adaptation to the higher 
metabolic rate.   
 
In order to determine whether Gpat4-/- mice are resistant to adipose tissue 
accumulation because of a broader influence on energy metabolism and to investigate 
the mechanism whereby GPAT4-deficient mice are protected from obesity, we 
characterized the growth and weight gain of littermate control and Gpat4-/- mice from 
birth to 8 weeks of age. Additionally, we evaluated the metabolic changes in female 
mice after a 4 week 45% fat diet challenge.  These studies enabled us to evaluate 
metabolic changes associated with a shift in dietary substrate before the onset of 
obesity, and indicated that the mice were hypermetabolic and had excess FA use in 
brown adipose tissue.  Although GPAT4 comprises 65% of the total GPAT activity in 
BAT, its role in this tissue had not been investigated (12).  Our studies provide evidence 
that the lack of GPAT4 protects mice from obesity because GPAT4 normally limits the 
oxidation of exogenously provided FA by brown adipocytes.  
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Results 
When dietary fat was the major macronutrient, the growth and weight gain in Gpat4-/- 
mice were impaired  
Gpat4-/- mice were a normal size at birth, but in contrast to the phenotype of 
mouse pups lacking GPAT1 (5) or GPAT3 (4), at weaning they were smaller than their 
littermates; by postnatal day 21, Gpat4-/- weanling mice had gained 25% less weight 
than controls and were 10% shorter (Fig 4.1A,B).  Between the second and the fifth 
week of life, the growth rate of the Gpat4-/- mice was slower than that of their littermates, 
but by six weeks of age the growth rates were similar (Fig 4.1C).  Adult female mice 
lacking GPAT4 are protected from diet-induced obesity (15), and we wondered whether 
the growth lag during the suckling period was due to the composition of mouse milk, in 
which TAG comprises 40 to 55% of total caloric energy (96).  To characterize an energy 
defect specifically associated with high dietary fat, control and Gpat4-/- mice were fed 
either a 10% fat (LFD) or 45% fat diet (HFD) for 8 weeks.  Weight gain was similar in 
genotypes fed the LFD.  When fed the HFD, control mice became obese and 
accumulated 3-fold more inguinal adipose tissue (Fig 4.1D,E).  In contrast, Gpat4-/- 
male mice remained lean, and inguinal adipose mass was similar regardless of diet.  
The lack of adipose tissue accumulation in Gpat4-/- mice was not due to a defect in TAG 
synthesis, because GPAT specific activity in inguinal adipose was identical in both 
genotypes (Fig 4.1F).  Representative photos illustrate the differences in body size at 
birth, p17, p28, and 8 weeks of age, and after 8 weeks of consuming the HFD (Fig 
4.1G).  These data suggest that mice lacking GPAT4 grow poorly when fat is the 
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predominant macronutrient in the diet, both during the suckling period and with high-fat 
feeding. 
 
GPAT4-deficient mice were hyper-metabolic with high-fat feeding 
Our data showing that both suckling Gpat4-/- pups and adults fed a high fat diet 
are consistent with a previous report that the metabolic rate of adult female Gpat4-/- 
mice is 5% higher than controls (15).  In order to determine whether the metabolic rate 
was higher during high-fat feeding, 8 week old control and Gpat4-/- mice were fed a 45% 
HFD for 4 weeks.  This short-term HFD allowed us to evaluate the metabolic effects of 
dietary fat content without the confounding variable of obesity.  The metabolic rate of 
Gpat4-/- mice fed the HFD was 12% higher than that of controls, with the major 
difference occurring primarily during the light cycle (Fig 4.2A).  Food consumption and 
physical activity were similar between genotypes (Fig 4.2B,C).  These findings suggest 
that the metabolic rate was accelerated in fat-fed Gpat4-/- mice. 
 
In the absence of GPAT4, the absorption of dietary TAG was not impaired 
It has been estimated that monoacylglycerol acyltransferase in intestinal 
epithelial cells is responsible for 75% of dietary TAG absorption (42).  Although GPAT 
activity is responsible for the remaining 25%, it is not able to rescue the deficit in fat 
absorption when monoacylglycerol acyltransferase-2 is absent (42).  To determine the 
importance of intestinal GPAT4 and whether its loss might play a role in the lack of 
weight gain of high fat-fed Gpat4-/- mice, GPAT activity was measured in intestinal 
mucosa from duodenum, upper and lower jejunum, and ileum.  Compared to control 
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duodenum and upper jejunum, total GPAT specific activities of Gpat4-/- mice were 90% 
and 40% lower, respectively (Fig 4.2D).  In the lower jejunum, total GPAT specific 
activity was similar in both genotypes, but in the ileum, the total GPAT specific activity of 
Gpat4-/- mice was 42% higher than that of controls, suggesting over-compensation by 
another GPAT isoform.  Because duodenal GPAT activity in Gpat4-/- mice was 90% 
lower than controls, we wondered whether malabsorption of dietary fat might have 
reduced weight gain in these mice. However, during the 6 h after an oral fat tolerance 
test, the amount of TAG accumulation in plasma did not differ between genotypes, 
showing that the immediate absorption of dietary TAG in Gpat4-/- mice was not delayed 
(Fig 4.2E).  To assess the impact of GPAT4-deficiency on fat absorption over a longer 
period of time, mice were housed individually and fed a 60% fat diet for one week.  The 
amount of fecal TAG was similarly low in both genotypes, consistent with normal TAG 
absorption (Fig 4.2F), and lipid staining in the intestinal mucosa was also similar in both 
genotypes, showing that dietary TAG had not accumulated without being absorbed (Fig 
4.2G).  Taken together, these data confirm that, despite severely depleted GPAT 
activity in the upper intestine of Gpat4-/- mice, TAG absorption remained normal.  It 
appears then, either that the activity of intestinal monoacylglycerol acyltransferase is 
sufficient for normal fat absorption or, less likely, that the upregulated GPAT activity in 
the ileum is sufficient to compensate for deficient absorption by the proximal intestine 
(42).     
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The increased metabolic rate of Gpat4-/- mice did not occur to maintain body 
temperature 
Consistent with an increase in metabolic rate that is unrelated to increased heat 
loss, the daytime temperature of Gpat4-/- female mice fed a HFD was 1ºC higher than 
controls (Fig 4.3A).  To determine whether the previously reported lack of subdermal 
adipose tissue in Gpat4-/- mice (5) eliminates a necessary insulating layer, 12 week old 
control and Gpat4-/- mice were challenged with a cold tolerance test.  Body 
temperatures during the challenge were similar between genotypes, suggesting that the 
insulating subcutaneous fat layer in Gpat4-/- mice was sufficient to prevent excessive 
heat loss (Fig 4.3B).  In addition, GPAT4 contributes minimally to total GPAT activity in 
white adipose tissue (Fig 4.1F) (1). Maintenance of body temperature during cold 
exposure relies on an animal’s ability to minimize heat loss and generate sufficient heat 
by shivering and BAT-mediated thermogenesis (97).  Because BAT is modifiable in 
rodents, extended periods of exposure to temperatures below thermoneutrality (~30oC) 
increases the thermogenic capacity of BAT.  In order to test thermogenic capacity, we 
measured the oxygen consumption rate after intraperitoneal injection of the β3-
adrenergic agonist, CL316243.  If the lack of subdermal adipose tissue were causing 
excessive heat loss, Gpat4-/- mice would increase oxygen consumption more than 
controls.  During the first hour after treatment with CL316243, the VO2 of both 
genotypes increased 15-20%, and during the second hour the VO2 remained 13-16% 
above baseline (Fig 4.3C).  The response to CL316243-stimulated VO2 is consistent 
with adequate heat retention by Gpat4-/- mice.  Similarly, the uptake of 2-deoxy[1-
14C]glucose into BAT was similar in Gpat4-/- mice and controls (Fig 4.3D).  Because 
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glucose uptake into BAT depends on the tissue’s thermogenic activation (98), the 
finding that glucose uptake was similar suggests an equivalent degree of thermogenesis 
at RT in both genotypes.  These responses strongly suggest that the hypermetabolic 
state of the Gpat4-/- mouse is not a response to maintain body temperature. 
 
Despite normal FA uptake, Gpat4-/- BAT contained less TAG than controls.   
Total and NEM-sensitive GPAT activity in Gpat4-/- BAT was 65% lower than 
controls, indicating that GPAT4 is the major GPAT activity in BAT (Fig 4.4A).  Gpat4-/- 
BAT from mice fed the LFD contained 17% less TAG than controls (Fig 4.4B), and BAT 
from mice fed the HFD contained 25% less TAG than controls.  To determine whether 
FA uptake was reduced in BAT, we measured the uptake of the non-metabolizable 2-
Br-[1-14C]palmitate.  The uptake of 2-Br-[1-14C]palmitate into BAT was similar in control 
and Gpat4-/- mice (Fig 4.4C), indicating that the lack of BAT TAG accumulation in 
GPAT4-deficient mice did not result from reduced FA uptake.  
 
Thermogenic gene expression increased in BAT from Gpat4-/- mice fed a HFD 
Fatty acids and acyl-CoAs are endogenous ligands for nuclear transcription 
factors, including peroxisome proliferator-activated receptors (PPARs) that, when 
activated, alter cellular energy metabolism (97).  Because Gpat4-/- BAT contained lower 
TAG stores but had normal FA uptake, we hypothesized that intracellular FA or acyl-
CoAs might influence the expression of PPAR target genes.  The expression of the 
PPARα target genes, Cpt1α, Pgc1α, Cte1, and Ucp1 was similar in control and Gpat4-/- 
mice fed a LFD (Fig 4.4D), but when Gpat4-/- mice were fed a HFD, Cpt1α, Pgc1α, 
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Cte1, and Ucp1 expression in BAT was 8, 12, 1.7, and 2.5-fold higher, respectively, 
than in controls (Fig 4.4D).  These diet-induced changes in gene expression suggest 
that the lack of GPAT4 might increase intracellular levels of FA or acyl-CoAs in BAT that 
might then signal to increase PPARα-mediated thermogenesis. 
 
In order to determine whether lack of GPAT4 increased the expression of PPARα 
target genes in other tissues, heart mRNAs were examined. Despite the fact that in 
Gpat4-/- hearts, total and NEM-sensitive GPAT activities were 25% and 33% lower than 
in controls, respectively (Fig 4.4F), the expression of these PPARα target genes was 
unaffected in mice fed either diet (Fig 4.4G), suggesting that there might be a threshold 
for GPAT4 activity whereby activity below this level results in upregulation of PPARα 
target genes.      
 
Mitochondria from Gpat4-/- BAT oxidized more fatty acid and glucose than controls 
To determine whether the diet-induced increases in PPARα target gene 
expression led to increased mitochondrial oxidation, we measured oleate and pyruvate 
oxidation in BAT mitochondria.  Mitochondria from control and Gpat4-/- mice fed a HFD 
were incubated with 200 µM [1-14C]oleate and after 30 min [14C]ASM and [14CO2] were 
measured.  Compared to controls, isolated mitochondria from Gpat4-/- BAT oxidized 
17% and 200% more oleate to ASM and CO2, respectively (Fig 4.4H).  Because the 
amount of [14C]CO2 was dramatically increased, these data suggested higher TCA cycle 
flux.  To test TCA cycle flux directly, we measured the oxidation of [2-14C]pyruvate.  
Note that use of [2-14C]pyruvate (rather than [1-14C]), permits the measurement of CO2 
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release after a complete cycle through the TCA cycle. When isolated mitochondria were 
incubated with 200 µM [2-14C]pyruvate, compared to controls, pyruvate oxidation to CO2 
in Gpat4-/- BAT was 150% higher (Fig 4.4I).  Thus, when GPAT4 was absent, TCA cycle 
flux in BAT mitochondria was enhanced.    
 
Adipogenesis was normal in primary brown adipocytes from Gpat4-/- mice  
Because in vivo BAT metabolism is altered by the thermal prehistory of the 
animal (97), the role of GPAT4 in brown adipose was determined in mature brown 
adipocytes that had been differentiated from primary Gpat4-/- pre-adipocytes.  
Compared to controls, total GPAT specific activity in primary adipocytes lacking GPAT4 
was 50% lower (Fig 4.5A).  To confirm that differentiation was normal, pre-adipocytes 
from control and Gpat4-/- neonates were cultured in differentiation media for 0 
(preadipocytes) or 7 (adipocytes) days and TAG accumulation and UCP1 expression 
were determined.  In both control and Gpat4-/- preadipocytes at day 0, TAG content and 
UCP1 expression were undetectable (data not shown).  Compared to controls, TAG 
content in differentiated brown adipocytes lacking GPAT4 was 20% lower (Fig 4.5B), 
and compared to day 0, the amount of UCP1 protein after 7 days of differentiation was 
markedly higher, but did not differ between genotypes (Fig 4.5C).  Thus, although 
GPAT4 is the major GPAT isoform in brown adipocytes, it is not required for normal 
brown adipocyte differentiation.  
 
GPAT4-deficient brown adipocytes oxidized more exogenous fatty acid than controls
 Because GPAT initiates the esterification pathway of complex lipid synthesis, we 
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hypothesized that GPAT4-deficient brown adipocytes would esterify less acyl-CoA, 
thereby allowing more acyl-CoAs to be oxidized.  To test this hypothesis, control and 
Gpat4-/- cells were incubated for 3 h with [1-14C]oleate.  Brown adipocytes lacking 
GPAT4 incorporated oleate into TAG at a 33% lower rate than controls, and oxidized 
oleate at a 40% higher rate (Fig 4.5D,E).  The incorporation of [1-14C]oleate into 
diacylglycerol and phospholipids was similar in cells from each genotype.  These results 
suggest that when high amounts of FA enter BAT, GPAT4 would normally divert the FA 
away from β-oxidation and toward esterification into TAG.  
 
Adding exogenous oleate to the culture media of brown adipocytes stimulates 
thermogenesis and FA oxidation (12).  To distinguish between the oxidation of 
endogenous and exogenous FA pools, a pulse-chase experiment was performed.  
Differentiated primary brown adipocytes from control and Gpat4-/- neonates were 
labeled with [9,10-3H]oleate for 1.5 h and the specific activity of the stored TAG was 
calculated.  To measure total oxidation, fresh media containing [9,10-3H]oleate was 
replaced for an additional 1.5 h.  To measure endogenous oxidation, labeled cells were 
switched to media containing unlabeled oleate and exogenous oxidation was calculated 
by subtracting endogenous oxidation from total oxidation.  Total oleate oxidation in 
Gpat4-/- brown adipocytes was 33% higher than controls (Fig 4.5F).  In both control and 
Gpat4-/- cells, more than 90% of the total oleate oxidized originated exogenously and, 
compared to controls, Gpat4-/- brown adipocytes oxidized exogenous oleate at a rate 
that was 45% higher (Fig 4.5F).  The remaining 10% of oxidized oleate originated from 
endogenous TAG stores and was oxidized at a similar rate by both genotypes.  These 
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results indicate that when brown adipocytes are exposed to a high oleate concentration, 
they primarily oxidize the exogenous oleate.  Because more oleate was oxidized by 
Gpat4-/- cells, it appears that the role of GPAT4 in BAT is to promote oleate storage as 
TAG and to diminish the availability of exogenous oleate for β-oxidation. 
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Discussion 
The initial report describing Gpat4-/- mice suggested that they were protected 
from diet and genetically-induced obesity, and that their higher metabolic rate at 2 
months resulted from an inadequate insulating subdermal adipose tissue layer (5).  The 
higher metabolic rate of Gpat4-/- mice was attributed to increased adaptive 
thermogenesis in BAT.  Because subdermal adipose tissue is minimally present until 2 
months of age (5), any absence of subdermal adipose in Gpat4-/- mice would not explain 
impaired growth during the suckling period.  Our findings suggest a different 
interpretation: that the increased metabolic rate resulted from the uncontrolled oxidation 
of excess exogenous FA by brown adipocytes.  Supporting this interpretation are data 
showing that Gpat4-/- female mice fed a HFD for 4 weeks had a metabolic rate that was 
12% higher and core body temperature 1oC higher than controls.  The higher metabolic 
rate and body temperature that occurs in Gpat4-/- mice is inconsistent with adaptive 
thermogenesis, which is designed to maintain normal body temperature.  In addition, 
mice lacking GPAT4 displayed normal cold tolerance, and they reacted normally to the 
β3-adrenergic agonist CL316243.  Taken together, these data indicate that the 
hypermetabolic state of Gpat4-/- mice is not a response to chronic heat loss.  
 
BAT thermogenesis is activated by cold exposure, β-adrenergic stimulation, and 
FA in a UCP1-dependent manner (99,100).  UCP1 is a gated pore that, when activated, 
permits the transport of protons across the inner mitochondrial membrane, thereby 
uncoupling the electron transport from ATP production (101).  Active BAT replenishes 
its intracellular lipid stores via uptake of FA from plasma (102,103).  Our data suggest 
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that GPAT4 is not only responsible for maintaining BAT TAG stores, but also for 
regulating the use of FAs by BAT. 
 
In addition to their metabolic roles in energy metabolism, FAs and acyl-CoAs 
derived from exogenous FAs or from the lipolysis of endogenous pools of TAG, act as 
ligands for the PPAR family of nuclear transcription factors, which have broad effects on 
cellular energy metabolism (104).  In HFD-fed Gpat4-/- mice, the increased mRNA 
abundance in BAT of the PPARα target genes, Cpt1α, Pgc1α, Cte1, and Ucp1, and the 
increased rate of oleate oxidation suggests an exogenous source of PPAR ligands.  
Lack of GPAT4, an enzyme present on the endoplasmic reticulum that is responsible for 
65% of the initial esterification of glycerol-3-P in BAT, might be expected to markedly 
diminish the rate of glycerolipid synthesis and allow more acyl-CoAs to enter the 
mitochondrial matrix for β-oxidation.  Additionally, because exogenous FAs entering 
brown adipocytes are effective PPARα ligands (105), the diminished capacity for FA 
esterification would allow FAs to be diverted to signaling pathways.  This interpretation 
is supported by data showing that GPAT4-/- primary brown adipocytes oxidized 
exogenous, but not endogenous, oleate at a higher rate than controls; thus, the lipid 
signals in Gpat4-/- BAT were probably either exogenous FAs or metabolites derived from 
FA oxidation.     
 
When the thermogenic effects of norepinephrine are blocked by the β-adrenergic 
receptor antagonist, propranolol, thermogenesis in brown fat cells can be stimulated by 
exogenous oleate (99), suggesting that exogenous FA can be oxidized independent of 
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lipolytic stimuli.  Consistent with these observations, when primary brown adipocytes 
were incubated with [3H]oleate, approximately 90% of the oxidized FA originated 
exogenously.  TAG turnover in working hearts is similar (106); the entry of high amounts 
of exogenous FA diminishes use of stored TAG for energy.  Because the lack of GPAT4 
in brown adipocytes resulted in a 45% higher rate of exogenous FA oxidation than in 
control cells, GPAT4 appears to limit FA availability for FA-induced thermogenesis.  
Importantly, in GPAT4-deficient primary hepatocytes, oxidation of exogenously derived 
FA is normal (107), suggesting that the mechanism whereby GPAT4 limits exogenous 
FA oxidation is specific to BAT and likely involves the FA-activated protein, UCP1.  
 
In brown adipocytes, maximal thermogenesis can be stimulated independently by 
oleate and by norepinephrine, but co-treatment is not synergistic (99), suggesting that 
FA-induced thermogenesis and cold-activated thermogenesis occurs through the same 
mechanism.  Although limiting cold-activated thermogenesis would be 
counterproductive, preventing the occurrence of thermogenesis induced by the 
presence of excess exogenous FAs would ensure optimal metabolic efficiency.  The 
abnormal thermogenesis that occurred with high fat feeding resulted in poor growth 
during the suckling period and a hypermetabolic phenotype in adults.  These 
consequences suggest that in BAT GPAT4 normally limits the oxidation of exogenous 
FAs, particularly when increased thermogenesis would be inappropriate.  Most studies 
find that high fat feeding increases Ucp1 mRNA and protein content, although the 
magnitude of the increases are variable and do not correlate with either the percent of 
dietary fat or the duration of the fat feeding (108).  The idea that excess calories might 
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provoke an increase in BAT-mediated energy wasting has seemed unlikely in an 
evolutionary sense, and the variability of the effect does not support it as a major 
feature of fat feeding.  However, the findings that Gpat4-/- pups consuming high fat milk 
grow poorly and that adult Gpat4-/- mice fed a HFD are hypermetabolic strongly suggest 
that, in the absence of cold exposure, GPAT4 is required to limit excessive oxidation of 
exogenous FAs.  When this limitation is absent, FA-induced thermogenesis induces a 
hypermetabolic state that is detrimental to the animal. 
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Experimental Procedures 
Materials 
Type I collagenase was from Worthington Biochemical Corporation.  [2-
14C]Pyruvic acid, [1-14C]oleic acid, and [9,10-3H]oleic acid were purchased from 
PerkinElmer Life Sciences.  Silica G gel plates were from Whatman.  Tissue culture 
plates were from BD Biosciences, and media were obtained from Invitrogen.  Sigma 
was the source of all other chemicals, unless otherwise indicated. 
 
Animal care  
Animal protocols were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee.  Mice were housed in a pathogen-free 
barrier facility on a 12-h light/dark cycle with free access to water and food (Prolab 5P76 
Isopro 3000; 5.4% fat by weight). Gpat4-/- mice have been backcrossed at least eight 
times onto a C57BL6/J background.  Gpat4-/- mice were compared to littermate controls, 
all born to heterozygous dams since homozygous females produce milk that is deficient 
in TAG (5).  Unless noted in the figure legends, female mice were used.  At 8 weeks of 
age, littermate controls and Gpat4-/- mice were either fed a control diet containing 10% 
kcal from fat or a matched high fat diet containing 45% kcal from fat, for either 4 or 8 
weeks (Research Diets D12450H and D12451, respectively).  Body weights were 
measured weekly.  Using a BAT10 thermometer with rectal probe attachment 
(Physitemp Instruments, Inc.), rectal temperature was measured between 10AM-12PM.  
To determine fecal TAG content, control and Gpat4-/- mice of both sexes were housed 
individually and fed a diet containing 60% kcal from fat (Research Diets, D12452).  
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Before collection of blood or tissues, food was removed from mouse cages for 4 hours, 
and mice were anesthetized with 250 mg/kg Avertin unless otherwise stated.  Body 
composition was determined with a 7T Bruker PharmaScan MRI system (Bruker 
BioSpin Corporation).  After the MRI, mice were placed in individual TSE Lab Systems 
metabolic cages (TSE Systems International Group) for 72 h to measure metabolic 
performance by indirect calorimetry.  To allow mice to acclimate, data were collected 
after the first 24 h in the metabolic cages.  Using the Weir equation (REE=[3.9(VO2) + 
1.1(VCO2)]1.44]), energy expenditure was calculated and normalized to the lean body 
mass of each mouse.  Before cold tolerance tests, 12 week old control and Gpat4-/- 
mice fed a 10% fat diet for 4 weeks were fasted for 4h.  Mice were placed into individual 
cages without food or bedding in a 4oC cold room.  Rectal temperatures were measured 
at 0, 1, 2, 3 and 4 h.  To measure VO2 in response to β-adrenergic stimulation, 12 week 
old control and Gpat4-/- mice fed a 10% fat diet for 4 weeks were placed into metabolic 
cages (TSE Systems International Group). Mice were transferred to TSE cages at 7AM 
and acclimated until 10AM.  Baseline O2 consumption measurements were collected 
from 10AM-1PM.  Mice were injected intraperitoneal with 5 mg/kg CL316243 at 1PM 
with measurements collected until 4PM. 
 
GPAT Activity 
After the diet challenge, tissues from control and Gpat4-/- mice were excised and 
frozen in liquid N2, and stored at -80oC until further use.  To obtain intestinal mucosa, 
intestines were resected, flushed with ice-cold phosphate-buffered saline (PBS), divided 
into four equal sections, and longitudinally dissected to expose the mucosa which was 
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scraped using a clean microscope slide.  One hundred milligrams of tissue was 
homogenized in ice-cold Medium I buffer (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM 
EDTA, 1 mM dithiothreitol) using 10 up-and-down strokes of a Potter-Elvehjem 
homogenizer.  Total membranes were isolated by centrifuging the homogenate at 
100,000 x g for 1 h.  GPAT initial rates were measured with 800 µM [3H]glycerol-3-
phosphate, and 82.5 µM palmitoyl-CoA (109).  The reaction was initiated by adding 10 
µg (cells) or 5-50 µg (tissue) of membrane protein after incubating the membrane 
protein on ice for 15 min in the presence or absence of 2 mM N-ethylmaleimide (NEM), 
which inactivates GPAT isoforms 2, 3, and 4.  NEM-resistant activity was calculated by 
subtracting NEM-sensitive activity from total activity.  The reaction products were 
extracted into CHCl3, dried under N2, resuspended in 4 mLs Cytoscint and counted on 
scintillation counter.  NEM-resistant activity (GPAT1) was calculated by subtracting 
NEM-sensitive activity from total activity.  
 
Measurement of Acute Lipid Absorption 
Twelve-week old control and Gpat4-/- mice were fasted for 4 h, anesthetized with 
isoflurane gas after which 200 µL of 15% Tyloxapol was injected into the retroorbital 
plexus to inhibit lipoprotein lipase activity and prevent TAG clearance by peripheral 
tissues (110).  Fifteen minutes after the Tyloxapol injection, blood was collected for 
baseline TAG measurement, and mice were gavaged with 200 µL olive oil.  Blood was 
collected via tail nick at 1, 2, 4, and 6 h after gavage. Plasma TAG was measured 
colorimetrically (Stanbio). 
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Lipid Extraction and TAG Measurement in Feces and Brown Adipose tissue and cells 
Feces were collected, pulverized under liquid nitrogen, and extracted by the 
Folch method (111).  Lysates from brown adipose and primary brown adipocytes were 
extracted similarly.  Chloroform extracts were dried under N2 gas and resuspended in 
200 µL tert-butanol:methanol:Triton X-100 (3:1:1, v:v:v).  TAG was determined as 
described above. 
 
Osmium Tetroxide Staining in Small Intestine 
The small intestine was resected, flushed with ice-cold PBS and divided into 3 
equal sections. Sections were fixed in 1.5% glutaraldehyde, neutral lipids were stained 
in 2% osmium tetroxide (112), and visualized using light microscopy. 
 
2-Br-[1-14C]palmitate and 2-Deoxy[1-14C]glucose Uptake 
To determine 2-Br-[1-14C]palmitate uptake, anesthetized mice were injected 
retroorbitally with 200 µL of 1% FA-free BSA solution containing 2 µCi 2-Br-[1-
14C]palmitate.  To determine 2-deoxy[1-14C]glucose uptake, 200 µL of sterile PBS 
containing 2 µCi 2-deoxy[1-14C]glucose was injected intraperitoneal.  For both 
experiments, blood was collected via tail nick 5 min after injection.  Thirty minutes after 
injection, tissues were excised, weights recorded, and snap-frozen in liquid N2.  Tissues 
were homogenized in 1 mL water with a blade homogenizer.  Aliquots of 250 µL tissue 
homogenates and 3 mL Ecolite were mixed in scintillation vials with radioactivity 
counted by a scintillation counter.   All measurements were performed in duplicate, and 
data were expressed as DPM/g tissue/DPM in 5 µL plasma 5 min after injection/30 min. 
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RNA Extraction and RT-PCR 
Extraction of total RNA, cDNA synthesis, and RT-PCR were performed using 
primer sequences and data normalization as described (113). 
 
Mitochondrial Isolation, and Fatty Acid and Pyruvate Oxidation 
BAT from control and Gpat4-/- mice fed a 45% fat diet were excised and 
mitochondria were isolated (113) and resuspended in mitochondrial isolation buffer 
containing 1 mM EDTA, 250 mM sucrose, 10 mM Tris-HCl pH7.8 and Complete 
protease inhibitor (Roche Biosciences).  Forty micrograms of mitochondrial protein was 
incubated at 37ºC with 200 µM [1-14C]oleic acid or [2-14C]pyruvic acid in a sealed tube.  
Note that use of [2-14C]pyruvate (rather than [1-14C]), permits the measurement of CO2 
release after a complete cycle through the TCA cycle. After 30 min, the reaction was 
stopped with 100 µL 70% perchloric acid and CO2 was liberated. CO2 was trapped in 
250 µL microcentrifuge tubes containing 1M NaOH by incubating the tubes at RT for 1 h 
with shaking. The acidified media were incubated overnight with 15% BSA and then 
centrifuged at 14,000 x g for 20 min.   Aliquots of the supernatant were counted for 
radiolabeled acid soluble metabolites (ASM), a measure of incomplete FA oxidation.  
Use of [2-14C]pyruvate (rather than [1-14C]), permits measurement of the release of 
[14CO2] after a complete cycle through the TCA cycle. 
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[1-14C]Oleate and [9,10-3H]Oleate Incorporation, Oxidation, and Lipid Extraction in 
Primary Brown Adipocytes  
Primary brown adipocyte precursors were isolated, cultured, and differentiated as 
described previously (114).  After isolation, cells were split twice to increase cell number 
and all experiments were performed at passage 2.  Sixteen hours before labeling, 
differentiation media was changed to pre-labeling media (DMEM, 1 g/L glucose, 10 mM 
HEPES, 10 % FBS).  Cells were incubated for 3 h with 1 mL of labeling media (DMEM, 
10 mM HEPES, 1 g/L glucose, 0.25% FA-free BSA, 1 mM carnitine) containing 500 µM 
[1-14C]oleic acid.  To distinguish between exogenous and endogenous FA oxidation, 
cells were incubated for 1.5 h with labeling media containing 500 µM [9,10-3H]oleic acid.  
Specific activity of brown adipocyte TAG stores was determined by dividing the 
radioactive counts in TAG by the nmol of TAG in brown adipocytes (DPM/nmol TAG).  
In parallel plates, media containing 500 µM oleic acid or 500 µM [9,10-3H]oleic acid was 
replaced for an additional 1.5 h.  In media from cells that were given media that 
containing unlabeled oleic acid, the oxidation metabolites recovered were from 
endogenous TAG stores (endogenous FA).  In the media of cells given labeling buffer 
containing [9,10-3H]oleic acid, radioactive oxidation metabolites were considered to 
represent total FA oxidation.  The amount of exogenous FA oxidation was calculated by 
subtracting the amount of endogenous FA oxidation from total FA oxidation.  
Radioactive oxidation metabolites in the media were extracted and measured as 
described above.  Cells were washed with pre-warmed PBS containing 1% BSA before 
lipids were extracted (84).  Lipid extracts and standards were separated by thin layer 
chromatography on Partisil LK5D Silica gel plates in a two-phase system: chloroform: 
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methanol: ammonium hydroxide (65:25:4, v/v/v) run to 50% of the plate, then air dried 
and run in heptane: isopropyl ether: acetic acid (60:40:4) to the top of the plate.  
Authentic lipid standards were visualized by iodine staining.  14C-labeled lipids were 
quantified with a Bioscan AR-2000 Imaging Scanner.  [3H]Labeled lipids were scraped 
from thin-layer chromatography plates, transferred to scintillation vials and counted. 
 
Statistics  
Data represent means ± standard error of the mean of at least three independent 
experiments performed in triplicate unless otherwise indicated.  In vitro models were 
analyzed by Student’s t-test comparing each genotype to controls.  In vivo models were 
analyzed by two-way analysis of variance and post-hoc comparisons of diet conditions 
within each genotype.  Data were considered significant with p < 0.05. 
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Figures 
	  
Figure 4.1: When dietary fat was the predominant macronutrient in the diet, 
Gpat4-/- mice gained less weight and were shorter than controls. A-C, Growth and 
weight gain of control littermate and Gpat4-/- male mice were characterized from birth 
until 8 weeks of age. A, Weight gain during nursing, B, total body length at birth (p0), 
postnatal day 17 (p17), postnatal day 28 (p28), and 8 weeks of age (p56).  C, Weekly 
growth rates of control littermate and Gpat4-/- male mice from birth to 8 weeks of age, 
n=20-35.  D-F, Control and Gpat4-/- male mice were fed a 10% fat (CD) or 45% fat diet 
(HFD) for 8 weeks. D, Weight gain and (E) inguinal adipose tissue mass, n=6 per 
genotype, diet. F, Total, N-ethylmaleimide sensitive, and N-ethylmaleimide resistant 
GPAT specific activity, n=6 per genotype.  G, Representative photographs of control 
littermate and Gpat4-/- male mice at p17, p28, 8 wks old and when fed a HFD for 8 wks. 
Data are presented ± SEM.  *p<.05, ANOVA 
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Figure 4.2: When fed a high-fat diet, Gpat4-/- mice were hypermetabolic.  A-C, 
Energy expenditure, physical activity, and food consumption in female control and 
Gpat4-/- mice fed a 45% fat diet for 4 weeks, n=6.  D, Total membrane preparations 
were obtained from littermate control and Gpat4-/- female mice fed a 10% fat diet for 4 
weeks.  Total GPAT specific activities were reported in four equal sections of the small 
intestine. E, Female control and Gpat4-/- mice fed a 10% fat diet for 4 weeks were 
gavaged with 200 µL olive oil.  Fifteen minutes prior to gavage, 500 mg/kg Tyloxapol 
was injected into the retroorbital plexus (to inhibit triacylglycerol clearance by peripheral 
tissues).  Blood was collected at 0, 1, 2, 4, and 6 h after gavage and plasma TAG were 
measured, n=5.  F, Fecal TAG content of littermate control and Gpat4-/- mice of both 
sexes.  Mice were individually housed and fed a diet containing 60% kcal from fat for 7 
days, n=5. G, Intestines from control and Gpat4-/- female mice fed a 45% HFD were cut 
into three equal sections, fixed in 1.5% glutaraldehyde, stained in 2% osmium tetroxide 
and visualized by light microscopy, n=4.  Data are presented ± SEM.  *p<.05, ANOVA. 
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Figure 4.3: GPAT4-deficient mice produce excess heat without constitutive heat 
loss.  GPAT4-deficient mice release excess heat without constitutive heat loss.  A, 
Daytime body temperature of female Gpat4-/- mice fed a 10% fat (CD) or 45% fat diet 
(HFD) for 4 weeks. Rectal temperature was measured between 10AM and 12PM, n=6 
per diet/genotype. B, Body temperature of fasted control and Gpat4-/- female mice 
exposed to 4oC for 4 h, n=5. C, Oxygen consumption rate in control and Gpat4-/- female 
mice after injection of CL-316243 (5 mg/kg), n=5. D, 2-Deoxy[1-14C]glucose uptake in 
BAT from control and Gpat4-/- female mice fed a 10% or 45% fat diet for 4 weeks, n=5-
6.  Data are normalized to tissue weight and radioactive counts in 5 µL plasma 5 min 
after i.p. injection.  Data are presented ± SEM. *p<.05 genotype, #p<.05 diet, ANOVA. 
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Figure 4.4: BAT in Gpat4-/- mice had an increased oxidative capacity.  A-F, Control 
littermate and Gpat4-/- female mice were fed a 10% fat (CD) or 45% fat diet (HFD) for 4 
weeks.  A, Total, N-ethylmaleimide sensitive and N-ethylmaleimide resistant GPAT 
specific activity in BAT, n=6 per genotype. B, BAT triacylglycerol content, n=6 per 
diet/genotype.  Thirty minutes after retroorbital injection of 2 µCi 2Br-[1-14C]palmitate, 
(C) 2Br-[1-14C]palmitate uptake into BAT was measured, n=5-6.  Data are normalized to 
tissue weight and radioactive counts in 5 µL plasma 5 min after retroorbital injection. D, 
mRNA expression of oxidation-related genes, n=6.  Data are normalized to the 
expression of 36B4.  E, Ucp1 protein levels.  F and G, GPAT specific activity and mRNA 
expression of oxidation-related genes in heart. H) BAT mitochondrial [1-14C]oleic acid 
oxidation to acid soluble metabolites (ASM) and carbon dioxide (CO2) and (I) [2-
14C]pyruvic acid oxidation to CO2, n=4. Data are presented ± SEM. *p<.05 genotype, 
#p<.05 diet, ANOVA. 
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Figure 4.5: Primary Brown Adipocytes lacking GPAT4 oxidize 46% more fatty acid 
than controls.  A-F, Brown adipocyte precursors were isolated from littermate control 
and Gpat4-/- neonates, cultured, and differentiated to mature brown adipocytes.  A, 
GPAT specific activity and (B) TAG content, n=3-6. C, Ucp1 protein levels in 
undifferentiated and differentiated brown adipocytes.  D and E, Differentiated brown 
adipocyte precursors from control and Gpat4-/- neonates were labeled with 500 µM [1-
14C]oleic acid for 3 hours.  Media were collected and (D) acid soluble metabolites (ASM) 
were extracted.  Cellular lipids were extracted in CHCl3:MeOH and separated by TLC to 
quantify [1-14C]oleic acid incorporation into (E) glycerolipids.  Differentiated brown 
adipocytes from control and Gpat4-/- neonates were incubated in the presence of (F) 
500 µM [9,10-3H]oleic acid for 1.5 h (total fatty acid oxidation) or 500 µM [9,10-3H]oleic 
acid for 1.5 h followed by 500 µM oleate for 1.5 h (endogenous fatty acid oxidation).  
Exogenous fatty acid oxidation rate was calculated by subtracting the endogenous fatty 
acid oxidation rate from the total fatty acid oxidation rate, n=4-6 animals per genotype 
across 3 independent experiments.  Data are presented ± SEM.  *p<.05, student’s T-
test. 
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Figure 4.6: GPAT4 limits the oxidation of exogenous fatty acids in brown 
adipocytes.  Under normal conditions, GPAT4 diverts exogenous fatty acids 
toward triacylglycerol (TAG) storage.  In the absence of GPAT4, those fatty acids 
are available for oxidation and to activate UCP1 to produce heat. 
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Chapter V: SEIPIN IS AN EVOLUTIONARILY CONSERVED REGULATOR OF 
GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (GPAT) – IN PROGRESS 	  
Summary 	  
Loss-of-function mutations of Seipin (also known as Berardinelli-Seip Congenital 
Lipodystrophy 2/BSCL2) cause the most severe form of human lipodystrophy.  Seipin 
can also regulate the formation and/or expansion of lipid droplets (LDs).  Recent studies 
have implicated Seipin in the metabolism of phosphatidic acid, however, the molecular 
function of Seipin has remained obscure. Here, we identify physical and functional 
interactions between Seipin and glycerol-3-phosphate acyltransferase (GPAT) isoforms 
that are located on the endoplasmic reticulum (Gat1 in yeast and GPAT3/4 in 
mammals); this interaction is evolutionarily conserved.  In Seipin-deficient yeast, 
mammalian cells, and in tissues from Bcsl2-/- mice GPAT specific activity is significantly 
increased.  The lack of Seipin changed GPAT kinetics by increasing Vmax and 
decreasing Km, suggesting an increased affinity for GPATs substrates, glycerol-3-
phosphate and 16:0-CoA.  During the first 12 h of differentiation, Seipin’s regulation of 
GPAT kinetics was essential to prevent an increase in intracellular PA levels.  Because 
Seipin deficiency impairs adipogenesis and alters lipid droplet morphology, we 
investigated the role of GPAT in mediating these functions.  When GPAT was 
overexpressed in yeast or mammalian cells, lipid droplets were larger and fewer in 
number than control cells, suggesting that increased GPAT activity was sufficient to 
recapitulate the effects of Seipin deficiency on LD morphology.  In contrast, although the 
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overexpression of GPAT1 and GPAT4 increased NEM-R and NEM-S GPAT activity, 
respectively, the overexpression of these isoforms did not block adipogenesis.  We 
hypothesize that the overexpression of GPAT3 will block adipogenesis (Experiments will 
be completed at time of dissertation defense).  Taken as a whole, these results identify 
Seipin as an evolutionally conserved regulator of microsomal GPAT and suggest that 
inhibition of GPAT activity might be a viable therapeutic strategy for restoring 
adipogenesis in lipodystrophic patients.     
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Introduction 	  
Congenital generalized lipodystrophy (CGL, also known as Berardinelli-Seip 
congenital lipodystrophy/BSCL), is an autosomal recessive disorder characterized by a 
near total loss of adipose tissue, severe hypertriglyceridemia, insulin resistance and 
fatty liver (69,115). To date, four genes have been linked to CGL/BSCL: 1-acylglycerol-
3-phosphate-O-acyl transferase-2 (AGPAT2)/CGL1; SEIPIN/CGL2; CAVEOLIN/CGL3 
and CAVIN/CGL4 (75). The most severe form of human CGL/BSCL is caused by loss-
of-function mutations in SEIPIN/BSCL2, which encodes an integral membrane protein of 
the endoplasmic reticulum (ER) with no recognizable functional domains (75,116,117). 
Seipin knockout mice (Bscl2-/-) suffer from severe lipodystrophy and insulin resistance 
(118-120), demonstrating in vivo an essential role of Seipin for adipogenesis.  
Importantly, Seipin and its orthologs also control the expansion of lipid droplets (LDs), 
as Bscl2-/-cells produce “supersized” LDs (71,73,74,121).  Therefore, Seipin has a 
unique role in regulating both systemic (adipogenesis) and cellular (LD expansion) lipid 
storage.  
 
Little is known about how the ER-localized Seipin may regulate both LD 
formation and adipogenesis.  Recent studies have implicated Seipin and its yeast 
ortholog Fld1 in regulating phospholipid metabolism (74).  In particular, an increase in 
the level of phosphatidic acid (PA) has been detected in a number of Seipin deficient 
cells/tissues (73,74).  Based on these findings, we have postulated that the increased 
PA may block PPARγ function and thus, preadipocyte differentiation.   Thus, 
intracellular PA may possess two distinct roles in serving as a PPARγ antagonist (77) 
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and promoting LD expansion in other cell types because of its fusogenic biophysical 
property (71,122).  However, because functional or catalytic domains in Seipin and its 
ortholog are not apparent, it is unlikely that Seipin itself functions as a glycerolipid 
synthetic enzyme.  
 
Through affinity isolation and tandem mass spectrometry analysis, we have 
identified a number of proteins that specifically co-precipitate with Fld1-GFP in the yeast 
Saccharomyces cerevisiae.  The most prominent of these proteins was a yeast glycerol-
3-phosphate acyltransferase (GPAT), Gat1.  We further demonstrate that mammalian 
Seipin specifically interacts with the corresponding mammalian glycerol-3-phosphate 
acyltransferase (GPAT) orthologs, GPAT3 and -4).  Seipin deficiency in yeast, 
mammalian cells, and tissues was associated with increased GPAT specific activity due 
to an increased affinity of GPAT for one of its substrates, glycerol-3-phosphate.  
Furthermore, overexpression of GPAT3 and GPAT4 was sufficient to induce the 
formation of “supersized” LDs.  In contrast, although the overexpression of GPAT1 and 
GPAT4 increased NEM-R and NEM-S GPAT activity, respectively, the overexpression 
of these isoforms did not block adipogenesis.  We hypothesize that the overexpression 
of GPAT3 will block adipogenesis. 
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Results 	  
Fld1 and Gat1 interact physically and functionally.3 
To identify potential Fld1p/Seipin interacting proteins, we expressed GFP alone, 
or a functional Fld1-GFP fusion protein using FLD1’s native promoter on a low copy 
plasmid in wild type or fld1Δ yeast cells (74).  Cell membranes were isolated and 
solubilized under three different buffer conditions (see Materials and Methods).  The 
extracts were then subjected to affinity purification using a GFP-Trap (123), and the final 
eluate was resolved by SDS-PAGE and stained with silver (Fig 5.S1).  Proteins were 
digested in-gel with trypsin, and the sequences of the resultant peptides were 
determined by tandem mass spectrometry. 
 
We identified 19 proteins that co-precipitated with Fld1-GFP, but not with matrix 
or GFP alone, in all three buffer/lysis conditions used (Table 5.S1).  Fifteen additional 
proteins specifically co-precipitated with Fld1-GFP in two of the three lysis conditions 
used (Table 5.S2).  Among the 34 proteins, two stand out: Gat1/Gpt2 and Ldb16.  
Ldb16 was recently identified to interact with Fld1, and the Fld1-Ldb16 complex was 
proposed to form the yeast ortholog of Seipin (124).  Gat1 and Gpt2 are highly 
interesting as they each encode one of the two GPATs expressed in yeast and initiate 
the synthesis of phosphatidic acid which has been proposed as the regulatory molecule 
controlled by Fld1/Seipin-tagged and overexpressed Fld1 and Gat1 can be specifically 
co-immunoprecipitated from yeast (Fig 5.1A, 5.S1B).  Importantly, this specific 
interaction was retained when both proteins were expressed at close to endogenous 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Data in this section contributed by Martin Pagac.	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levels by adding tags at the C-termini of their respective genomic loci (Fig 5.1B).  As 
recently reported (74), we were also able to co-immunoprecipitate Fld1 and Ldb16 
expressed at close to endogenous levels (Fig 5.1B) and to co-immunoprecipitate Ldb16 
and Gat1 (Fig 5.1C).  Fld1 can also be co-immunoprecipitated with Gat2, a yeast GPAT 
that shares ~38% sequence identity and ~58% sequence similarity with Gat1 (Fig 
5.1D).  We then examined the physical relationships among Fld1, Ldb16 and Gat1 and -
2.  The Fld1-Gat1 interaction was not affected in ldb16 null cells (Fig 5.1E).  Thus, it 
appears that Fld1, Ldb16 and Gat1/2 form a ternary complex, but that Ldb16 is not 
required for the Fld1-Gat1/2 interaction.  We were not able to test whether the Ldb16 
and Gat1/2 interaction requires Fld1 because Ldb16 is extremely unstable in the 
absence of Fld1. 
 
Mammalian Seipin and GPAT3/4 physically interact4 
We wondered if the Seipin-GPAT interaction was conserved in mammals.  To 
date, four mammalian GPATs have been identified; GPAT1 and GPAT2 localize to 
mitochondria outer membrane, and GPAT3 and GPAT4 are present on the ER (28).  
GPAT1 is resistant to sulfhydryl reagents like N-ethylmaleimide (NEM), whereas 
GPAT2, 3 and 4 are sensitive.  Seipin can be co-immunoprecipitated with both GPAT3 
and GPAT4 in 3T3 L1 cells (Fig 5.2A, 5.S2A,B).  Notably, the interaction between 
GPAT3/4 and a Seipin missense mutant (T78A) that is linked to human lipodystrophy 
was significantly weakened (Fig 5.2B,C).  The C-terminal cytoplasmic region of Seipin 
does not seem to be required for this interaction (Fig 5.2D).  Importantly, endogenous 
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GPAT3/4 can be immunoprecipitated by overexpressed Seipin (Fig 5.2E,F).  Finally, we 
employed the proximity ligation assay to further examine the Seipin-GPAT3/4 
interaction. GPAT3 and GPAT4 are much closer to Seipin than AGPAT2 (Fig 5.2G) 
and, consistent with Fig. 2D, full length, but not the carboxy terminus of Seipin, interacts 
strongly with GPAT3/4 (Fig 5.2F). 
 
In SEIPIN-deficient cells and tissues, GPAT activity was higher than controls 
Because Seipin and GPAT physically interact, we hypothesized that Seipin 
regulates GPAT activity.  In order to test this hypothesis, we measured GPAT activity in 
control and fld1 null yeast cells.  Consistent with our hypothesis, microsomal GPAT 
activity in fld1 null yeast cells was ~35% higher than controls (Fig 5.3A).  To determine 
whether Seipin also regulates GPAT activity in mammalian cells, we compared 
microsomal GPAT activity in control and Bscl2-/-/Seipin-/- mouse embryonic fibroblasts 
(MEFs).  Consistent with our observations in yeast, compared to controls, GPAT 
specific activity in Bscl2-/- mEFs was approximately 2.5-fold higher (Fig 5.3B).  
Surprisingly, when Seipin was replaced by retroviral overexpression in Bscl2-/- mEFs 
GPAT specific activity remained 2.5-fold higher than controls, suggesting that 
microsomal GPAT was no longer accessible to Seipin.  Next, we used shRNA to knock 
down Seipin in 3T3L1 preadipocytes and measured GPAT specific activity in the 
presence and absence of NEM, which inhibits GPAT2, 3, and 4.  With each shRNA, 
Seipin was knocked down by ~70%, and total GPAT activity in these cells was two-fold 
higher than in control cells (Fig 6.5D).  In both control and Seipin knockdown cells, 
NEM-resistant GPAT activity was only 10% of the total activity, thus, the higher GPAT 
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activity in Seipin knockdown cells was largely due to NEM-sensitive GPAT activity (Fig 
5.3C).  Finally, to determine whether the absence of SEIPIN would also alter GPAT 
activity under more complex physiological conditions, in control and Bscl2-/- mouse 
testis we measured GPAT activity.  Compared to controls, in Bscl2-/- testes NEM-
sensitive GPAT activity was 67% higher (Fig 5.3D).  Importantly, Seipin knockdown did 
not increase the mRNA or protein expression of any GPAT isoforms, confirming that the 
higher GPAT activity in the absence of Seipin was not due to increases in GPAT mRNA 
expression or protein levels (Fig 5.S3A-H).  Taken together, these data demonstrate 
that Seipin regulates GPAT activity and that this regulatory role is conserved from yeast 
to mammals. 
 
Seipin deficiency altered GPAT kinetics 
In the absence of compensatory GPAT expression, the higher GPAT activity in 
Seipin-deficient cells and tissues suggested that Seipin might regulate GPAT enzyme 
kinetics.  In order to test the effect of Seipin deficiency on GPAT enzyme kinetics, we 
characterized the affinity of GPAT for its two substrates, glycerol-3-phosphate and long-
chain acyl-CoA.  Acyl-CoA is an amphipathic molecule and a detergent that, at higher 
concentrations, disrupts membranes (125).  Thus, because GPAT activity is inhibited at 
palmitoyl-CoA concentrations higher than 82.5 µM, the apparent Km values for acyl-
CoA cannot be calculated in cells or tissues (Fig 5.4I-P).  In control mEFs GPAT 
showed an apparent Km for glycerol-3-phosphate of 241.3 µM (Fig 5.4C, D); however in 
Bscl2-/- mEFs, the apparent Km for glycerol-3-P was 517.9 µM, suggesting that Seipin-
deficiency increases GPATs affinity for glycerol-3-P.  Despite the fact that Seipin 
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overexpression in Bscl2-/- mEFs did not inhibit steady state GPAT activity (Fig 5.3B), in 
these cells the apparent Km was 249.8 µM, suggesting that the replacement of Seipin 
was sufficient restore GPAT substrate affinity to control levels.  Compared to that in 
yeast and mEFs, in 3T3L1 preadipocytes, Seipin regulated GPAT kinetics in a similar 
manner.  In control preadipocytes, the apparent Km for G3P was 216.6 µM and in 
shRNA-Seipin preadipocytes the apparent Km for G3P was 117.6 µM (Fig 5.4E,F). 
Because Seipin is most highly expressed in the testis, we also characterized GPAT 
enzyme kinetics in that tissue.  Similar to the yeast and mammalian cells, the apparent 
Km for glycerol-3-P in Bscl2-/- testes was 454.2 µM whereas in control testis the 
apparent Km for G3P was 578.1 µM (Fig 5.4G,H).  Therefore, because the absence of 
Seipin increased GPAT activity and shifted its apparent Km for glycerol-3-P in yeast, 
preadipocytes, mEFs, and testis we concluded that Seipin is an evolutionarily 
conserved regulator of GPAT.        
 
Increased GPAT activity underpins the change in LD morphology in Seipin-deficient 
cells5  
Increased GPAT activity may also cause the formation of “supersized” LDs and 
increased PA in fld1 null cells. Indeed, overexpressing wild type, but not catalytic-dead 
GAT1 and GAT2 in yeast cells leads to the formation of supersized LDs (Fig. 5.5A, 
5.S5A), phenocopying fld1 null cells. The level of PA in the ER was similarly increased 
in these cells, as in fld1 null cells, as indicated by increased INO1 expression (Fig 
5.5B). Despite the presence of large LDs, the total amount of TAG was not significantly 
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increased in these cells (Fig 5.S5B), and Importantly, when either GAT1 or GAT2 was 
co-expressed with FLD1, few supersized LDs were detected. 
 
Seipin deficiency in mammals is associated with clustered LDs in fibroblasts and 
cell lines, and with supersized LDs in the testes where Seipin is normally highly 
expressed.  By increasing GPAT activity, these changes can be recapitulated.  When 
GPAT3/4 are overexpressed in 3T3-L1 cells, LDs appear enlarged and clustered (Fig 
5.5C).  
 
During adipogenesis, Seipin regulates GPAT kinetics and increased GPAT1 and 
GPAT4 activity did not impair differentiation. 
 Because Seipin deficiency is associated with increased GPAT activity and 
altered GPAT kinetics we hypothesized that Seipin would regulate GPAT kinetics during 
differentiation.  To test this hypothesis, control and shBSCL2 3T3L1 cells were 
differentiated for 0, 4, 8, and 12 h and GPAT kinetics were measured.  Consistent with 
this hypothesis, Seipin deficiency altered GPAT kinetics at 0 and 4 h of differentiation.  
In differentiating control cells, the apparent Km for glycerol-3-phosphate was 175.6, 
267.1, 176.2, and 153.1 µM, respectively (Fig 5.6A,C).  In contrast, in Seipin 
knockdown cells, the apparent Km for glycerol-3-phosphate was 113.3, 146.7, 141.8, 
138.4 µM, respectively (Fig 5.6B, C).  Because the differences in GPAT kinetics were 
transient and occurred within the first 4 h of differentiation, suggests that the regulation 
of GPAT by Seipin is required for an early step in adipogenesis.  To test the effect of 
Seipin deficiency throughout differentiation, we used lentivirus expressing GFP or 
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shRNA targeting BSCL2 to construct stable 3T3L1 cells and differentiated them for 0 h, 
12 h, 24 h, 48 h, and 8 d.  Compared to controls, in shBSCL2-expressing cells Seipin 
mRNA was reduced by ~70% at 0 h and remained low throughout differentiation (Fig 
5.6D).  Consistent with the role for Seipin in differentiation, shBSCL2-expressing cells 
were unable to differentiate and Seipin deficiency virtually abolished PPARγ expression 
(Fig 5.6E).  These findings are consistent with previous reports that Seipin deficiency 
blocks PPARγ activation early in differentiation (126) and provide evidence to suggest 
that the regulation of GPAT by Seipin is required for normal adipogenesis. 
 
 Because Seipin deficiency impairs adipogenesis and increased GPAT activity, 
we investigated whether increased GPAT activity would be sufficient to block 
adipogenesis.  To do so, 3T3L1ΔCar cells were infected with adenovirus 
overexpressing eGFP, GPAT1, or GPAT4 and tested their ability to differentiate.  First, 
we confirmed that overexpression of GPAT1 and GPAT4 increased GPAT activity.  
Compared to eGFP expressing cells, the overexpression of GPAT1 and GPAT4 
increased NEM-R and NEM-S GPAT activity ~3-fold, respectively (Fig 5.6F).  In 
contrast to our hypothesis that increased GPAT activity was sufficient to block 
adipogenesis, neither the overexpression of GPAT1 nor GPAT4 prevented PPARγ 
activation (Fig 5.6G).  That GPAT1 overexpression did not block adipogenesis is 
unsurprising because GPAT1 overexpression did not increase NEM-S GPAT activity to 
levels seen in Seipin-deficient 3T3L1 cells (Fig  5.3C).  However, because Seipin 
physically interacted with GPAT4 and GPAT4 overexpression increased GPAT activity 
to a similar level to that in Seipin-deficient cells, these findings are perplexing.  Either 
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our hypothesis about GPAT activity and adipogenesis is incorrect or the increased 
GPAT activity in Seipin-deficient cells is not due to increased GPAT4 activity, but 
possibly increased GPAT3 activity.  To test this possibility, we have overexpressed 
GPAT3 in this system and plan to measure the ability of GPAT3-overexpressing cells to 
differentiate.  These data will be complete by the date of my defense. 
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Discussion 	  
Seipin’s role is unique role in mammalian lipid storage because it regulates both 
cellular (LDs) and systemic (adipogenesis) lipid storage.  However, as an integral 
membrane protein of the ER without any known functional domains, Seipin’s function 
has been difficulty to understand.  Here, we demonstrate that Seipin orthologs can 
interact specifically with the ER-located GPAT isoforms, and that this evolutionarily-
conserved interaction inhibits both the specific activity of GPAT and its affinity for 
glycerol-3-P.  Our data provide additional evidence that enhanced GPAT activity in the 
ER of Seipin-deficient cells increases the level of PA, inhibits adipogenesis in 
preadipocytes, and modulates LD formation and growth in other cell types.   
 
GPAT catalyzes the acylation of glycerol-3-P and initiates the pathway of TAG 
and phospholipid synthesis. There are four GPAT isoforms in mammalian cells, each 
encoded by a separate gene.  Both GPAT1 and GPAT2 localize to mitochondria but 
GPAT1 is resistant to NEM whereas GPAT2 sensitive.  The microsomal, NEM-sensitive 
GPAT is encoded by two closely related genes, GPAT3 and GPAT4.  The ER 
(microsomal) GPAT activity is conserved from yeast to humans as both GPAT isoforms 
in yeast are integral membrane proteins of the ER.  Although GPAT controls the rate-
limiting step in the synthesis of both TAG and phospholipids, the regulation of 
microsomal GPAT activity remains largely unknown, and to our knowledge, no GPAT 
interacting proteins have been identified.   
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Here, we show Seipin interacts with GPAT3/4 in an evolutionarily conserved 
manner to regulate GPAT enzyme kinetics.  This interaction and regulation is highly 
conserved from yeast to mammalian cells and tissues.  Furthermore, we provide 
evidence that increased GPAT activity is the underlying cause of the aberrant lipid 
droplet morphology in Seipin deficient yeast and mammalian cells.  Finally, we are 
working to determine whether increased GPAT activity is sufficient to block 
adipogenesis.  If this hypothesis were true, then GPAT might be a suitable therapeutic 
target for the treatment of type 2 CGL.     
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Experimental Procedures 	  
Isolation of Fld1 interacting proteins using GFP-Trap 
Yeast wild type cells transformed with plasmid pLacYCP-GFP and fld1Δ cells 
transformed with pLacYCP-Fld1-GFP were grown to early stationary phase and then 
lysed using bead beater in the following buffers: buffer #1 (25 mM Tris-HCl pH 8.0, 150 
mM NaCl, 0.5% Triton X-100, 0.2 mM EDTA, 0.2 mM DTT); buffer #2 (20 mM K-HEPES 
pH 7.4, 110 mM KOAc, 150 mM NaCl, 0.1% Triton X-100, 0.1% Tween 20, 2 mM 
MgCl2); buffer #3 (20 mM K-HEPES pH 7.4, 110 mM KOAc, 150 mM NaCl, 0.1% Triton 
X-100, 0.1% Tween 20, 46 mM n-octyl-B-D-glucopyranoside, 2 mM MgCl2, 5% 
glycerol). Each lysis buffers also contained a mixture of protease (1 mg/mL PMSF, 1 
mg/mL phenanthroline, 3 µg/mL leupeptin, 15 µg/mL Pepstatin) and phosphatase (2 
mM NaF, 2 mM Na3VO4) inhibitors except that buffer #2 did not contain phenanthroline. 
Cell lysates were initially incubated with Sepharose CL-4B (GE Healthcare) to pull down 
proteins interacting with beads, and the supernatants were subjected to affinity 
purification using a GFP-Trap (ChromoTek GmbH, Martinsried, Germany) to pull down 
proteins interacting with GFP and Fld1-GFP, respectively.   
 
Identification of Fld1 interacting candidates using mass spectrometry 
Proteins were eluted from the Sepharose and GFP-Trap beads with a low pH 
buffer (pH2) containing 100 mM glycine, neutralized and separated on 4-15% Tris-HCl 
gels (Bio-Rad). After staining with Coomassie Brilliant Blue R-250 (Sigma), protein 
bands were digested in-gel with trypsin [Shevchenko, A., Wilm, M., Vorm, O., and 
Mann, M. (1996) Mass spectrometric sequencing of proteins silver-stained 
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polyacrylamide gels. Anal Chem 68, 850-858] and the sequences of the resultant 
peptides were determined by liquid chromatography tandem mass spectrometry using 
LTQ-Orbitrap Velos Pro (Thermo Fisher Scientific) coupled to UltiMate 3000 RSLC 
(Dionex). Mass spectra were acquired in data-dependent mode with one 30,000 
resolution MS survey scan in the Orbitrap (350-1750 m/z) followed by up to 10 MS/MS 
scans triggered above intensity of 2500 using CID (normalized collision energy 35) in 
ion trap. The raw files were processed in Proteome Discoverer software (Thermo 
Scientific) using default parameters. The fragmentation spectra were searched against 
the SwissProt protein database using the Mascot search engine (Matrix Science). One 
missed tryptic cleavage was allowed, carbamidomethylation of cysteines was set as a 
fixed modification, and methionine oxidation, protein N-terminal acetylation, glutamine 
and asparagine deamidation were used as variable modifications. The precursor and 
fragment mass tolerances were set to 5 ppm and 0.5 Da, respectively. Both peptide and 
protein identifications were filtered at 1% false discovery rate. The list of candidate 
interactors was created from proteins identified in at least two FLD-GFP pull-downs and 
not present in any of the controls (Sepharose and GFP alone pull-downs).  
 
Cell culture 
HeLa and NIH3T3 cells were grown in Dulbecco’s Minimum Essential Medium 
(DMEM) supplemented with 10% FBS (Invitrogen). Transient transfections of plasmids 
were performed using the calcium phosphate method. Small interfering RNA (siRNA) 
oligos were transfected using the Lipofectamine RNAiMAX reagent (Invitrogen). SiRNAs 
(SiBscl2-1 and siBscl2-2 against murine Bscl2, siBSCL2-1, and siBSCL2-2 against 
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human BSCL2) were from Sigma; their sequences are shown in Supplementary Table I. 
To induce TAG synthesis and LD formation, cells were treated with 200 µM BSA-
conjugated oleate (molar ratio of oleate to BSA ∼8:1) 48 h after transfections and 
incubated for 16 h. 
 
Lentivirus Production and Stable Cell Line Generation 
One control and two shBSCL2 lentiviral constructs were used to generate 10 mL 
of lentivirus in HEK293 cells using a 2nd generation lentivirus packaging system and 
Roche X-tremeGENE HP Transfection Reagent.  To generate stable 3T3-L1 cells with 
each lentivirus, cells were incubated overnight with 1 mL of lentivirus containing 8 
µg/mL polybrene.  After selecting stable cell lines with 4 µg/mL puromycin for 1 wk, cells 
were used for experiments or stored in liquid N2. 
 
3T3-L1 Cell Culture and Differentiation Time course 
Cells stably expressing lentivirus empty vector, shBSCL2-1, or shBSCL2-2 were 
grown to confluence in DMEM, 10% calf serum, 4 mM glutamine and 100 U/ml 
penicillin/streptomycin.  After reaching confluence, cells were grown for an additional 2 
d in fresh growth media.  Differentiation was initiated by culturing cells in DMEM, 10% 
FBS, 4 mM glutamine, antibiotics and 1 µM dexamethasone, 250 nM IBMX, and 1 µg/ml 
insulin for 2 days.  Two days later fresh DMEM and 10% FBS with 1 µg/ml insulin was 
added and refreshed every 2 days.  Cells were rinsed with room temperature PBS and 
frozen in plates at 0, 12, 24, 48 h, and 8 days of differentiation.  For GPAT activity and 
PA measurements, plates were frozen after 0, 4, 8 and 12 h of differentiation.  
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Phosphatidic Acid Measurement 
Total cell lipid was extracted (84) and PA content was analyzed by LC/MS (127).  
The amount of each PA species in the biological samples was calculated from the peak 
areas obtained using software that controls the LC/MS system (Analyst 1.5, Applied 
Biosystems).  Raw peak areas were corrected for recovery and sample loading, and 
transformed into amounts of analyte, using standard curves made with commercially 
obtained glycerolipids.  Glycerolipids were quantified with 0.1 nmol 17:0 LPA as an 
internal standard to correct for recovery.  PA was quantified and normalized to protein 
concentrations of the cellular lysates. 
 
Adenoviral Overexpression of GPAT in 3T3L1ΔCar cells 
 3T3L1ΔCar cells were provided by David Orlicky.  To enhance their ability to be 
infected, Dr. Orlicky engineered these cells to overexpress the coxsackie/adenovirus 
receptor (128).  These modifications do not affect normal adipocyte function.  
Adenovirus expressing eGFP, GPAT1, and GPAT4 were obtained from the UNC Vector 
Core (14).  When cells reached 90% confluence, they were infected with adenovirus in 
serum-free Optimem containing virus at 25 MOI for 2 hours.  After 2 hours, fresh 3T3L1 
growth media were replaced and cells were grown for an additional 72 h prior to 
differentiation.  Differentiation protocol was the same as described above.  
 
GPAT Activity Assay 
One hundred milligrams of tissue or cells from 10 cm plates were homogenized 
in cold Medium I (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM 
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dithiothreitol) using 10 up-and-down strokes with a Teflon-glass motor-driven 
homogenizer.  Total membranes were isolated by centrifuging the homogenate at 
100,000 x g for 1 h.  GPAT specific activity (initial rate) was assayed for 10 min at RT in 
a 200 µl reaction mixture containing 75 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 1 mg/ml 
BSA (essentially fatty acid–free), 1 mM dithiothreitol, 8 mM NaF, 800 µM [3H]glycerol-3-
phosphate, and 82.5 µM palmitoyl-CoA (109). The reaction was initiated by adding 25-
50 µg of testis membrane protein or 5-10 µg of cellular membrane protein after 
incubating the membrane protein on ice for 15 min in the presence or absence of 2 mM 
NEM, which inactivates GPAT isoforms 2, 3, and 4 (109). The reaction products were 
extracted into 2 mL CHCl3 and measured as described (109).  NEM-resistant activity 
(GPAT1) was calculated by subtracting NEM-sensitive activity from total activity.  To 
determine the reaction products, 1 mL CHCl3 was dried under N2, resuspended in 30 µL 
CHCl3:CH3OH (2:1; v/v), and separated by TLC (CHCl3:pyridine:88% formic acid, 
50:30:7; v/v).  Greater than 90% of the reaction product was PA; the remainder was 
lysophosphatidic acid. 
 
GPAT Activity Enzyme Kinetics 
Total particulate protein (5 µg) from control and Bscl2-/- mEFs and 3T3L1 cells 
stably expressing lentivirus empty vector or shBSCL2 was used to determine enzyme 
kinetics.  To measure enzyme dependence on [3H]glycerol-3-P, the palmitoyl-CoA 
concentration was held at 82.5 µM and [3H]glycerol-3-P concentrations were varied (40-
400 µM).  Palmitoyl-CoA concentrations above 82.5 µM inhibited the reaction.  
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Plasmid constructions 
Strains, primers and plasmids are listed in Table S1. 
 
Co-immunoprecipitations 
The following antibodies were used: mouse and rabbit anti-V5 (Santa Cruz 
Biotechnology, 1:2’000), mouse anti-FLAG (Clontech, 1:1’000), mouse anti-Dpm1 (Life 
Technologies, 1:250), rabbit anti-Ldb16, rabbit anti-Erg1, rabbit anti-Are2 (kind gifts 
from Dr. C.W. Wang, 1:500; 1:8’000; 1:2’000), mouse anti-HA (Covance, 1:1’000), 
rabbit anti-HA (Cell Signaling, 1:1’000), rabbit anti-Calnexin (Cell Signaling, 1:1’000), 
rabbit anti-Calreticulin (Abcam, 1:1’000), rabbit anti-Actin (Sigma, 1:1’000), rabbit anti-
AGPAT6/GPAT4 (Origene, 1:1’000). 
 
Yeast cells were grown at 30°C in defined media containing glucose or galactose 
as the carbon source and amino acids as required. Cells were washed with ice-cold 
PBS, frozen at -80°C for at least 2 h. Cells were lysed in IP Lysis/Wash buffer [0.5% 
(w/v) CHAPS, 150 mM NaCl2, 2 mM EDTA, 25 mM HEPES, pH 7.4, 1 mM DTT, 5% 
Glycerol, Sigma Protease Inhibitor Cocktail, 1 mM PMSF] by vortexing 6 x 1 min with 
glass beads, and cooling the tubes on ice between each cycle. Cell lysates were 
incubated for 30 min on ice, then centrifuged at 1,000 x rcf for 5 min at 4°C to remove 
intact cells and debris. The supernatant was further centrifuged at 17,000 x rcf for 45 
min at 4°C to pellet insoluble material. Protein concentration in the supernatant was 
determined by the BCA method, and 2 mg of protein were used for each co-
immunoprecipitation condition. For mouse anti-FLAG antibody and mouse anti-V5 
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antibody immunoprecipitations, each antibody was immobilized on magnetic 
Dynabeads® according to the Dynabeads® Co-Immunoprecipitation Kit manual.  
After 30 min of incubation with the cell lysates containing over-expressed protein at 
room temperature, or after overnight incubation with the cell lysates containing low-
levels of recombinant protein at 4°C, the beads were washed 5 times with IP 
Lysis/Wash buffer and eluted in 2 x non-reducing SDS PAGE sample buffer at 37°C for 
20 min for western blotting. Proteins were transferred onto PVDF membranes in CAPS 
buffer, pH 11.0, followed by immunodetection.  
 
Transiently or stably transfected mammalian cells, mouse embryonic fibroblasts 
(MEF), mouse preadipocytes (3T3-L1), and HeLa cells, were washed three times with 
ice-cold PBS and lysed in IP Lysis/Wash buffer (see above) containing either 0.5% (w/v) 
CHAPS or 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM) by forcing the cells 30 times 
through a 0.8 mm needle. Cell lysates were incubated for 60 min at 4°C on the wheel to 
solubilize membrane proteins, then the lysate was centrifuged at 17,000 rcf for 60 min 
at 4°C to pellet insoluble material. Protein concentration in the supernatant was 
determined by the BCA method, and 2 mg of protein were used for each 
coimmunoprecipitation condition. 
 
Cell lysates were pre-cleared for 2 h at 4°C with agarose beads, or with mouse or 
rabbit IgG-Dynabeads®. After 60 min of incubation with the cell lysates containing over-
expressed recombinant protein at room temperature, or after overnight incubation with 
the cell lysates containing endogenous GPAT3 and GPAT4 at 4°C, the beads were 
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washed 3 times with IP Lysis/Wash buffer, then eluted in 2 x non-reducing SDS PAGE 
sample buffer at 37°C for 20 min for western blotting. Proteins were transferred onto 
PVDF membranes in CAPS buffer, pH 11.0, followed by immunodetection. 
 
Antibodies, immunoprecipitation, immunofluorescence, and immunoblot 
DsRed polyclonal antibody to detect mCherry and fusion proteins (Clontech), 
Flag monoclonal antibody (Sigma), actin monoclonal antibody (Abcam), and HA and 
Myc monoclonal antibodies (Covance) were purchased. For immunoprecipitation, cells 
were lysed with Lysis buffer B, 50 mM Hepes-KOH, pH 7.4/100 mM NaCl/1.5 mM 
MgCl2/0.5% (v/v) CHAPSO containing protease inhibitors (27). Cell lysates were passed 
through a 22-gauge needle 5 times, extracted by rotating for 1 h at 4°C, and clarified by 
centrifuging at 100,000 x g for 15 min. The lysates were precleared by incubation for 1 h 
at 4°C with 50 µl of protein G sepharose beads (Sigma). Precleared lysates were 
rotated overnight at 4°C with 10 µg of monoclonal anti-Flag together with 50 µl of 
protein G sepharose beads. Pelleted beads were washed three times (10 min at 4°C) 
with 1 ml of Lysis buffer B containing protease inhibitors, resuspended in 80 µl of 2× 
SDS sample buffer, boiled for 5 min, and subjected to SDS/10% PAGE and immunoblot 
analysis. 
 
For immunofluorescence, cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.1% saponin/PBS for 30 min, then blocked with 3% BSA/0.05% 
saponin in PBS for 1 h. Cells were incubated with primary antibodies diluted in 1% 
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BSA/PBS for 1 h, then incubated with Alexa Fluor 568 conjugated secondary antibodies 
for 1 h. 
 
For immunoblot analysis, cells were lysed with Lysis buffer A and passed through 
a 22-gauge needle 5 times and clarified by centrifugation at 3,000 x g for 5 min. 
Samples were subjected to SDS/10% PAGE, transferred to nitrocellulose filters, and 
subjected to immunoblot analysis. Bound antibodies were visualized by 
chemiluminescence using ECL Western blotting detection reagents (GE Healthcare). 
For Blue Native PAGE, HeLa cells transfected with wild-type or mutant forms of 
mCherry- or Flag-tagged Seipin were lysed with Lysis buffer B.  After clearing 
unsolubilized debris by centrifugation at 13,000 x g for 10 min, lysates were loaded onto 
4-16% NativePAGE gels (Invitrogen) for protein separation. Flag- and mCherry-tagged 
seipin were probed with anti-Flag and anti-mCherry, respectively. 
 
Statistics 
For statistics, experiments were performed in triplicates. The results are 
presented as mean ± SD. Two-tailed Student's t-test was used for comparison. 
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Figures 
 
	  
Figure 5.1: Fld1, Ldb16 AND Gat1/2 form a ternary complex in yeast.6  A) 
Coimmunoprecipitation of overexpressed Gat1-V5 and FLAG-Fld1 by V5 antibody from 
yeast lysates. (V5 antibody does not immunoprecipitate FLAG-Fld1 in absence of Gat1-
V5. Dpm1 can only be detected in the input).  B) Using FLAG antibody, endogenous 
levels of Gat1-V5 and Ldb16 coimmunoprecipitate with FLAG-Fld1 from yeast cell 
lysates. (FLAG antibody does not immunoprecipitate Gat1-V5 or Ldb16 in absence of 
FLAG-Fld1. Dpm1 and Erg1 can only be detected in the input).  C) 
Coimmunoprecipitation of endogenous levels of Gat2-V5 and FLAG-Fld1 by FLAG 
antibody from yeast lysates. (FLAG antibody does not immunoprecipitate Gat2-V5 in 
absence of FLAG-Fld1.  D) Using FLAG antibody, endogenous levels of Gat1-V5 and 
Ldb16 coimmunoprecipitate with FLAG-Fld1 and mutant GLR-Fld1-FLAG from fld1Δ or 
ldb16Δ yeast cell lysates. (FLAG antibody does not immunoprecipitate Gat1-V5 or 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  Results from Martin Pagac.	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Ldb16 in absence of FLAG-Fld1. Coimmunoprecipitation of Gat1-V5 and Ldb16 with 
mutant GLR-Fld1-FLAG is weakened). 
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Figure 5.2: Mammalian Seipin and GPAT3/4 physically interact.7 
A) Coimmunoprecipitation by FLAG and HA antibody of overexpressed FLAG-tagged 
GPAT3 or GPAT4 and HA-tagged Seipin, respectively, from transfected mEF cell 
lysates. (FLAG-GPAT3 and -GPAT4 and HA-Seipin do not immunoprecipitate in 
absence of the bait. Calnexin and Actin can only be detected in the input, see Figure S. 
A).  B) and C) Coimmunoprecipitation by HA antibody of overexpressed HA-tagged 
mutant or wild-type Seipin forms from stably FLAG-GPAT3 and -GPAT4 transfected 
3T3-L1 cell lysates. (Coimmunoprecipitation of FLAG-GPAT3 and FLAG-GPAT4 with 
mutant HA-T138A-Seipin is weakened. The mutant HA-A272P-Seipin form is not stable 
in 3T3-L1 cells. Calnexin and Actin can only be detected in the input).  D) Using HA 
antibody, FLAG-tagged GPAT3 and -GPAT4 coimmunoprecipitate with a series of 
overexpressed HA-tagged C-terminal Seipin truncations, but not with the HA-tagged 
Seipin C-terminus. (Calnexin and Calnectin can only be detected in the input).  E) 
GPAT4 antibody detects a specific band of ∼50 kDa in lysates from three different 
mouse liver tissue homogenates, but also from lysates isolated from two different 
GPAT4-/- mouse liver tissues. (The band detected in GPAT4-/- mouse liver tissue lysates 
derives likely from GPAT3, as the peptide used to raise the GPAT4 antibody in rabbit is 
96% identical to the corresponding GPAT3 sequence).  F) Using HA and FLAG 
antibody, endogenous GPAT4 and GPAT3 coimmunoprecipitate from lysates prepared 
from stably HA- and FLAG-Seipin transfected 3T3-L1 adipocytes. (HA and FLAG 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  Courtesy of Martin Pagac.	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antibodies do not immunoprecipitate GPAT4 and GPAT3 in the presence of FLAG-
Seipin and HA-Seipin, respectively).	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Figure 5.3: GPAT activity is significantly increased in Fld1/Seipin-deficient cells 
and tissues. 
A) GPAT specific activity in control and fld1Δ yeast microsomes. GPAT activity was 
measured by adding 7.1 mM [14C]glycerol-3-P and 50 µM acyl-CoA (1:1, C16:0- and 
C18:1-CoA) to 100 µg microsomes and reactions were allowed to proceed for 10 mins.  
Lipids were extracted and incorporation of [14C]glycerol-3-P into lipids quantified by 
scintillation counting.   B-D) GPAT activity was measured by adding 5, 10, or 15 ug of 
total particulate protein, in the presence or absence of 2 mM N-ethylmaleimide (NEM) 
for 15 mins, to a reaction mixture containing 800 µM [1,2,3-H]glycerol-3-phosphate and 
82.5 µM 16:0-CoA.  Reactions were terminated after 10 mins and lipids were extracted 
into CHCl3, dried and quantified by scintillation counting.  NEM-Sensitive (NEM-S) 
GPAT activity was calculated by subtracting NEM-resistant (NEM-R) GPAT activity from 
total GPAT activity.  B) GPAT specific activity in control and Bscl2-/- mEF cells, and 
Bscl2-/- cells containing overexpressed HA-tagged Seipin.  C) GPAT specific in control 
and shBSCL2-expressing 3T3-L1 cells.  D)  GPAT specific activity in control and Bscl2-/- 
testis.  N=2-3, Results are shown as mean ± S.E.M. *p<.05, student’s T-test.	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Figure 5.4: GPAT kinetics were altered in Seipin-deficient cells and tissues. 
A-H) Glycerol-3-phosphate dependence and Lineweaver-Burk plots.  A and B) BY and 
fld1 yeast. C and D) Control and Bscl2-/- mouse embryonice fibroblasts.  E and F) 
Control and shRNA knockdown of Seipin in 3T3L1 cells.  G and H) Control and Bscl2-/- 
testis.  Five micrograms of membrane proteins were incubated in the presence of 
increasing amounts of [1,2,3-H]glycerol-3-phosphate (50-800 µM). I-P) Palmitoyl-CoA 
dependence and Lineweaver-Burk plots.  I and J) BY and fld1 yeast. K and L) Control 
and Bscl2-/- mouse embryonic fibroblasts. M and N) Control and shRNA knockdown of 
Seipin in 3T3L1 cells. O and P) Control and Bscl2-/- testis.  Palmitoyl-CoA 
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concentrations were varied from 11.25-82.5 µM. Q) Summary table for kinetics.  
Reactions were terminated after 10 mins, lipids extracted into CHCl3, dried and 
quantified by scintillation counting.  N=2-3 for each group represents cells from 3 
different cell passages.  Results are shown as means ± S.E.M.  
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Figure 5.5: Activation of GPAT drives the formation of supersized LDs in yeast 
and mammalian cells.8 
A) LDs of BY4741 wild-type (WT), SLD-forming yeast strains (O/E Gat1 and O/E Gat2) 
and mutants (O/E Gat1 G262D and O/E Gat2 G253L) grown in SC media until early 
stationary phase. Cells were stained with Nile red and immediately observed for LDs 
under a fluorescence microscope.  B) INO1 mRNA levels in WT, fld1Δ, Gat1 O/E and 
Gat2 O/E yeast strains. Increased INO1 mRNA levels indicate increased PA levels in 
the ER membrane.  C) 3T3-L1 control cells (mock) or stably expressing Flag-tagged 
GPAT3 or GPAT4 were treated with oleate-BSA complexes for 16 h, fixed, and then 
stained with BODIPY 493/503 for lipid droplets. Representative confocal images are 
shown. Immunoblotting analysis of total cell lysates with anti-Flag or anti-NPC1. 
Diameters of top 3 largest lipid droplets in each cell. Data represent mean ± SD (***p < 
0.001). 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  Contributed by Martin Pagac.	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Figure 5.6: During differentiation, Seipin regulates GPAT kinetics and increased 
GPAT1 or GPAT4 activity does not block adipogenesis.  A-C) GPAT kinetics in 
control and shBSCL2 3T3L1 preadipocytes at 0, 4, 8, and 12 h of differentiation.  
Results shown are Lineweaver-Burk plots with 1/specific activity in y-axis and 
1/[glycerol-3-phosphate] in the x-axis.  Five micrograms of membrane protein was 
incubated in the presence of increasing amounts of [1,2,3H]-glycerol-3-phosphate (50-
800 µM) for 10 mins.  D) In 3T3L1 cells, lentiviral knockdown reduces Seipin mRNA by 
70% at 0 h and it remains low throughout differentiation.  E) During differentiation, 
lentiviral knockdown of Seipin prevents normal PPARγ expression.  F) In 3T3L1ΔCar 
cells, adenoviral overexpression of GPAT1 and GPAT4 increases N-ethylmaleimide 
resistant (NEM-R) and sensitive (NEM-S) GPAT activity, respectively.  G)  During 
differentiation, GPAT3 overexpression, but not that of GPAT1 or GPAT4, blocks PPARγ 
expression.  mRNA expression was normalized to 36B4 expression.  The expression of 
this gene does not change with differentiation status.  Results shown are from 3 
different cell passages or 3 independent infections and are presented as the mean ± 
S.E.M.   	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Figure 5.S1: Fld1, Ldb16 AND Gat1/2 form a ternary complex in yeast.9 
A,B) Coimmunoprecipitation of overexpressed Gat1-V5 and FLAG-Fld1 by V5 antibody 
from yeast lysates. (FLAG-Dga1 does not coimmunoprecipitate with Gat1-V5. V5 
antibody does not immunoprecipitate FLAG-Fld1 in absence of Gat1-V5. Dpm1 and 
Are2 can only be detected in the input).  C) Coimmunoprecipitation of Ldb16 with 
mutant GLR-Fld1-FLAG, compared to wild-type Fld1-FLAG, is weakened.	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  Contributed by Martin Pagac.	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Figure 5.S2: Mammalian Seipin and GPAT3/4 physically interact.10 
A) Inputs used for the coimmunoprecipitation experiment described in Figure 2 A).  B) 
Coimmunoprecipitation by FLAG antibody of overexpressed FLAG-tagged GPAT3 or 
GPAT4 and HA-tagged Seipin, respectively, from transfected HeLa cell lysates. (HA-
Seipin immunoprecipitates equally in the presence or absence of FLAG-GPAT3).	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  Contributed by Martin Pagac.	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Figure 5.S3: GPAT activity is significantly increased in Fld1/Seipin-deficient cells 
and tissues. 
A,B) Gat1 mRNA and protein expression in control and fld1Δ yeast microsomes.  
Dpm1p is used as loading control.   C,D) GPAT3/4 mRNA and protein expression in 
control and Bscl2-/- mEFs or Bscl2-/- cells containing overexpressed HA-tagged Seipin 
(OE Seipin).  mRNA expression was normalized to 36B4 and GAPDH was used as 
protein loading control.  E,F) GPAT3 and GPAT4 mRNA levels in control and shBSCL2-
expressing 3T3L1 cells. mRNA expression was normalized to 36B4.  Western blots are 
in progress.  G,H) GPAT3/4 mRNA expression in control and Bscl2-/- testis.  mRNA 
expression was normalized to β-actin.  Western blots are in progress.  	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Fig 5.S5: Activation of GPAT drives the formation of “supersized” LDs in yeast 
and mammalian cells.11 
A) Protein levels of O/E Gat1-V5 and G262D, O/E Gat2-V5 and G253L are similar. 
Normal LD size in yeast containing O/E catalytically dead Gat1 and Gat2 is not due to 
lower enzyme levels.  B) Relative neutral lipid level quantification by thin layer 
chromatography.  C) Thin layer chromatography separation of neutral lipids (TAG) and 
stearoyl ester (SE). Used for quantifications in Figure 5.S5B).  D) Cells were grown until 
early stationary phase in SC media, stained with Nile red, and examined by 
fluorescence microscopy. LDs of mutant strains O/E Dga1 and pah1Δ. SLDs were 
present in pah1Δ strains but not in the O/E Dga1 strain.	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Chapter VI: SYNTHESIS 	  
 The focus of this dissertation was to elucidate independent functions of GPAT 
isoforms.  Hepatic GPAT1, but not GPAT4, was required for the incorporation of de 
novo synthesized fatty acids into TAG and to divert fatty acids away from β-oxidation 
(Ch. III).  Thus, despite catalyzing a similar amount of GPAT activity in the liver, GPAT1 
and GPAT4 perform distinct and non-redundant functions.  The differences in the 
functions of hepatic GPAT1 and GPAT4 are likely due to variations in subcellular 
location, acyl-CoA preference, or nutritional regulation.  In contrast to its role in liver, 
GPAT4 limits the oxidation of exogenous fatty acids in brown adipocytes (Ch. IV).  The 
disparate functions of GPAT4 in liver and BAT suggests that compartmentalization of 
glycerolipid synthesis is tissue-dependent.  Finally, (Ch. V) we provide preliminary data 
suggesting a novel role for Seipin as an evolutionarily conserved regulator of 
microsomal GPAT activity.  In both yeast and mammalian cells, Seipin physically 
interacted with microsomal GPAT, and the loss of Seipin increased GPAT activity.  The 
activity of GPAT was increased because GPAT had a higher affinity for one of its 
substrates, glycerol-3-phosphate.  Taken together, the work in this dissertation provides 
strong evidence that the flux of acyl-CoAs toward glycerolipid synthesis is 
compartmentalized and that each GPAT isoform performs a specific function within a 
physiological context. 
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Directions for Future Research 
How do cells compartmentalize glycerolipid synthesis? 
Enzyme complexes 
   Little work has been done to examine the interactions of membrane-bound 
metabolic enzyme complexes, but some examples are available.  In the intestinal 
lumen, dietary TAG is hydrolyzed to 2 fatty acid constituents and a 2-monoacylglycerol.  
Once these components are transported into the intestinal epithelium, fatty acids are 
reesterified to the 2-monoacylglycerol, packed into chylomicrons and secreted into the 
lymph.  The rate-limiting enzyme in intestinal TAG resynthesis is catalyzed by 
monoacylglycerol acyltransferase isoform-2 (MGAT2).  MGAT2 esterifies an acyl-CoA 
to the sn-1 position of the 2-MAG to produce PA, and subsequent acyl-CoA 
esterification is catalyzed by DGAT1 to produce TAG.  To enhance the efficiency of 
these reactions, it seems likely that these proteins might interact.  Interestingly, in Cos-7 
cells, MGAT2 heterodimerizes with DGAT1 and in McArdle rat hepatoma cells, it 
heterodimerizes with DGAT2 (129,130).  The fact that these interactions differ in a cell 
type-dependent manner suggests that MGAT2 may have additional interacting partners 
in other tissues.  Because these enzymes are found in complexes, it is likely that GPAT 
and other lipid metabolism enzymes interact in a similar manner. 
 
In the Coleman lab, experiments are underway to identify protein-protein 
interactions of the acyl-CoA synthetase isoform-1 (ACSL1).  ACSLs activate fatty acids 
to fatty acyl-CoAs before their use in downstream metabolic reactions, including 
complex lipid synthesis.  Pamela Young has generated stable cell lines that 
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overexpress ACSL1 tagged with BirA.  This BirA tag biotinylates enzymes that come 
into close contact with ACSL1 and, once biotinylated, these proteins can be purified with 
streptavidin, and identified with an unbiased proteomics approach.  Once protein-protein 
interacting partners are identified, the interactions can be confirmed using co-
immunoprecipitation.  By performing these experiments in different cell-types and 
examining interactions with different physiological stimuli, these studies will provide 
direct evidence of cell type-dependent interactions that vary in response to physiological 
stimuli.  A similar approach can be undertaken to identify interacting proteins with GPAT 
proteins.   
 
Reorganization of organelles   
 Located on the outer mitochondrial membrane, GPAT1 and 2 produce LPA that 
is incorporated into TAG.  However, the second enzyme, AGPAT, is thought to be 
exclusively located on the ER.  Thus, how the GPAT-derived LPA on the outer 
mitochondrial membrane is accessible to ER-bound AGPAT enzymes remains unclear.  
Because GPAT1 does not move from the mitochondria (37), it is possible that certain 
physiological conditions result in the association of the mitochondria and ER and permit 
GPAT1-derived LPA to be accessible to the downstream metabolic enzymes in TAG 
synthesis.  Studies using confocal microscopy might be best suited to reveal 
interactions between metabolic enzymes on distinct organelles.  Alternatively, 
mitochondrial-derived LPA may be bound to an intracellular fatty acid binding protein 
(FABP) that directs its transport toward the enzymes on the ER (131).  Acetate-labeling 
studies similar to those completed in Chapter III could be performed in various FABP-
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null hepatocyte models and determine if deletion of FABP produces a similar result to 
GPAT1 deficiency. 
 
Movement of enzymes to different intracellular compartments 
 Recent evidence demonstrates that the full complement of TAG synthetic 
enzymes moves from the bilayer of the ER onto the outer leaflet of LDs, and this 
movement is required for LD expansion (37).  Incubation with oleate induces relocation 
of GPAT4, AGPAT2, and DGAT2.  The overexpression of these proteins increases the 
size of lipid droplets within cells.  It remains unclear how this movement is controlled, 
however, recent studies have identified the ER protein Seipin as essential for controlling 
LD biogenesis.  Loss of Seipin results in increased LD size, likely mediated via its 
interaction with GPAT3 or GPAT4.  How this interaction regulates GPAT4 and LD size 
remains obscure.  It is possible that Seipin restricts the movement of GPAT4 or that 
Seipin controls the production of the fusogenic lipid, PA.  This possibility would suggest 
that release of Seipin from GPAT4 increases local PA production and induces fusion of 
LDs and ER, permitting movement of TAG synthetic enzymes onto LDs.  Further 
studies using confocal microscopy and an intracellular probe for PA will be useful in 
elucidating these mechanisms. 
 
 A second question relates to the activity of membrane-bound enzymes on the 
monolayer of LDs.  All of the TAG synthetic enzymes are predicted to have at least two 
strongly hydrophobic domains, suggesting that they traverse the ER bilayer.  Their 
movement onto the outer leaflet of LDs would likely alter their conformation, thus, 
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modifying their enzymatic activities.  Whether these enzymes retain their activity on the 
outer leaflet of the LD has not been confirmed, but is supported by their coordinated 
movement and LD expansion.  It is possible that the conformational change resulting 
from relocation to LDs alters the kinetics of these enzymes and increases their activity.  
To confirm this, methods need to be developed to measure enzyme activity on LDs.  
Purification of LDs is commonly used in proteomic screens that identify LD-associated 
proteins, however, the close association of LDs and ER prohibits entirely pure fractions 
and may contaminate LD fractions and obscure results.  Further, the amount of protein 
found on the LDs is low and requires an excess of material to permit measurement of 
enzymatic activity.  Additionally, the amount of lipid within the droplet fractions may 
confound enzymatic assay measurements.  Nonetheless, development of adequate 
techniques to measure LD-associated enzyme activity would provide valuable 
information with regard to LD biogenesis. 
 
Do lipid droplets segregate into functional pools? 
Lipid droplets and the “athletes paradox” 
The overexpression of GPAT1 and GPAT4 results in dramatic differences in LD 
size and number.  Whereas the overexpression of GPAT1 increases the number of LDs, 
these droplets are decidedly smaller.  In contrast, GPAT4 overexpression increases the 
size of LDs.  These differences in LD dynamics may inform the “athlete’s paradox”.  
Although the accumulation of TAG in skeletal muscle of obese individuals is associated 
with insulin resistance, highly trained athletes also accumulate excess TAG, but remain 
exquisitely insulin sensitive.  However, the mechanisms remain obscure.  Based on the 
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known roles of GPAT1 and GPAT4 in LD biogenesis, it is possible that the GPAT 
isoform that catalyzes TAG synthesis in muscle from obese individuals and highly 
trained athletes is different.  It is possible that the resulting lipid droplets either contain 
differences in the complements of proteins, interactions with organelles, or GPAT-
derived lipid intermediates that alter distinct signaling pathways that affect larger 
metabolic pathways.  Theoretically, one could obtain muscle biopsies from obese and 
highly trained individuals and measure the incorporation of radiolabeled fatty acid into 
lipid.  These results would provide preliminary data to begin exploring which GPAT 
isoform is involved in each process.  Alternatively, GPAT assays could be performed on 
these samples to determine whether GPAT1 or an alternate GPAT isoform catalyzes 
the predominant amount of GPAT activity in the respective samples. 
 
GPAT-derived lipid droplets in BAT thermogenesis 
 Similar to the athletes’ paradox, TAG accumulation in BAT is observed in obesity 
and in cold-acclimated rodents.  Because GPAT4 limits oxidation of exogenous fatty 
acids in brown adipocytes and loss of GPAT4 does not affect acute cold tolerance (Ch. 
IV), it is possible that an alternate GPAT isoform is important for BAT TAG accumulation 
in cold-acclimation.  Consistent with differential nutritional regulation of GPAT isoforms, 
mitochondrial GPAT activity in BAT is upregulated 3-fold with exposure to an acute cold 
challenge and nearly 7-fold following a 21-day cold exposure.  In contrast, microsomal 
GPAT activity is unchanged in response to an acute cold exposure, and following a 21-
day cold challenge, is increased 2 to 3-fold (132).  Consistent with the regulation in cold-
exposed rodents, β -adrenergic stimulation did not alter microsomal GPAT activity, but 
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mitochondrial GPAT activity was increased 5-fold (133).  To distinguish the role of the 
mitochondrial and microsomal GPAT isoforms in BAT thermogenesis, direct comparison 
of GPAT-null mice in response to cold-acclimation is necessary.  Furthermore, direct 
comparison of fatty acid incorporation into GPAT-null primary brown adipocytes will 
provide valuable information regarding acyl-CoA metabolism in β-adrenergic activated 
brown adipocyte cells.  With the interest in BAT activation as a potential therapeutic 
target for the treatment of obesity, these studies may prove particularly informative.  
 
GPAT Double-knockout models 
 Based on the variable phenotypes of GPAT-null mice, curiosity has arisen with 
respect to the simultaneous deletion of multiple GPAT isoforms.  Because GPAT1 and 
GPAT4 are the predominant GPAT isoforms in liver, deletion of both isoforms would 
provide valuable information on the ability of other GPAT isoforms to compensate. 
Deletion of both microsomal GPAT isoforms, GPAT3 and GPAT4, would permit us to 
determine the necessity of differentially localized GPATs, i.e. Can mitochondrial GPATs 
fully compensate for the loss of all microsomal GPAT activity.  Assuming that the loss of 
both microsomal GPATs would produce viable offspring, one could potentially identify 
additional microsomal GPAT isoforms.  To avoid the potential for embryonic lethality, 
one could inducibly delete the second GPAT after birth.  Despite our current 
understanding that GPAT1 is the only NEM-resistant GPAT isoform, GPAT1-deficient 
hearts retain NEM-resistant GPAT activity, suggesting that an alternate GPAT isoform is 
present in cardiac tissue.  Together, these studies could identify new GPAT isoforms 
and explain the necessity of GPAT isoforms in different intracellular locations. 
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How does GPAT subcellular location affect function? 
 Because our evidence supports the hypothesis that the metabolism of acyl-CoAs 
through GPAT is highly compartmentalized, it is likely that some of this is due to 
differences in subcellular location.  Zengying Wu, a member of the Coleman Lab, is 
currently investigating the relationship between GPAT location and function.  To do so, 
Zengying is modifying the signal peptide of microsomal GPAT4 to target this enzyme to 
the outer mitochondrial membrane.  Results from these studies will inform questions 
related to GPAT location and function.  An alternate approach could be used to evaluate 
the importance of the C-terminus of GPAT1.  Using a cloning approach, one could add 
the C-terminus of GPAT1 to either microsomal GPAT isoform and subsequently 
measure sensitivity to NEM or the ability to use various acyl-CoA substrates. 
 
Do GPATs possess other enzymatic activities? 
 GPAT isoforms possess four highly conserved motifs that are essential for their 
catalytic activity.  Leading to their initial identification as AGPATs, the microsomal 
GPATs possess a fifth motif, present in the AGPAT family of enzymes.  Although 
subsequent studies show that both GPAT3 and GPAT4 possess GPAT activity, some 
work suggests that GPAT3 may also express AGPAT activity.  However, the techniques 
used to isolate membranes for AGPAT activity assays limit this conclusion.  
Furthermore, plant GPAT enzymes are bifunctional enzymes that possess sn-2 
acyltransferase activity and phosphatase activity, suggesting the potential for 
mammalian GPATs to exhibit dual functions.  When William Lands first identified the sn-
1 specificity of GPAT (134), the discovery of four distinct GPAT isoforms had not been 
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made.  Thus, further biochemical characterization of the GPAT enzyme substrate 
preference and positional specificity is necessary.   Determining the potential for 
AGPAT or other enzymatic activities in GPATs would provide valuable insights into the 
flux of acyl-CoAs towards specific glycerolipid fates and lipid intermediate signals. 
 
Seipin and GPAT: impact on lipodystrophy and LD biogenesis 
Does the overexpression of GPAT block adipogenesis? 
 	   Based on our preliminary findings (see manuscript 3), we hypothesize that in 
Seipin-deficient cells, increased GPAT activity underpins the block of adipogenesis.  To 
test this, we plan to overexpress GPAT3 and GPAT4 in 3T3L1 preadipocytes and 
measure their ability to differentiate.  Differentiation will be determined by measuring the 
mRNA expression of PPARγ and Oil Red O staining of neutral lipids to confirm lipid 
accumulation.  We will confirm that GPAT activity is increased with overexpression and 
send samples to our collaborator Thurl Harris at the University of Virginia for mass 
spectrometric identification of PA species.  These experiments are currently underway. 
 
How does increased GPAT activity in Seipin-deficient cells impair adipogenesis? 
 With the discovery that Seipin is an evolutionarily conserved regulator of 
microsomal GPAT activity and the observation that Seipin deficiency increased GPAT 
activity, our next step is to determine the mechanism for how GPAT activity impairs 
adipogenesis.  Our collaborator on this project, Hongyuan (Rob) Yang at the University 
of New South Wales has proposed a theory that links the increased intracellular PA 
levels in lipodystrophic tissues to the inhibition of PPARγ activation.  This theory posits 
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that increased GPAT activity leads to increased intracellular PA and that PA acts as an 
antagonist to PPARγ activation (77).  Based on our previous studies on the action of di-
16:0-PA in the insulin-signaling pathway, it is possible that microsomal GPAT generates 
a PA specie with an acyl-chain composition that acts as a potent antagonist to PPARγ.  
To address this question, we have overexpressed GPAT3 and GPAT4 in 3T3L1 cells 
and will use mass spectrometric studies, with our collaborator Thurl Harris at the 
University of Virginia, to compare the PA species that are elevated in both Seipin-
deficient and GPAT overexpressing cells.  If our hypothesis is correct, we would expect 
that the PA species in Seipin-deficient tissues and cells overexpressing GPAT would be 
similar to those lacking Seipin.  By identifying those PA species that were specifically 
increased in these cells, but not in GPAT4 overexpressing cells, we could test the 
potential of the identified PA species as antagonists of PPARγ.  Although it has been 
proposed that PPARγ is modulated by naturally occurring lipid, no endogenous ligands 
have been identified.  Results from these studies would reveal the molecular 
mechanism for Seipin-deficient lipodystrophy and identify the first endogenous ligand for 
the master regulator of adipogenesis, PPARγ.   
 
Does the lack of Seipin alter AGPAT activity? 
 Because the lack of Seipin increases GPAT activity and intracellular PA levels, it 
is possible that AGPAT, the enzyme that synthesizes PA from LPA, activity is also 
increased.  My preliminary data suggests that in Seipin-deficient cells, AGPAT activity is 
increased when 16:0-CoA, but not 18:1-CoA, is used as an acyl-donor.  If we are able to 
confirm these findings then we will proceed with characterization of the enzymatic 
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kinetics and substrate preference of this activity.  Whether this activity is catalyzed by 
an AGPAT isoform or by one of the microsomal GPAT isoforms will also require further 
investigation. 
 
How does Seipin regulate LD biogenesis through GPAT? 
 Current evidence supports that Seipin’s interaction with GPAT4 is required to 
control the movement of GPAT4 on to the outer leaflet of growing LDs.  Studies to 
identify how this interaction modulates LD biogenesis are currently underway in our lab 
and in several labs within our field.  Whether Seipin restricts the movement of GPAT4 
onto the droplet or mediates the fusion of LDs with the ER membrane remains unclear.  
Alternatively, it is possible that Seipin modifies the potential for microsomal GPATs to 
catalyze AGPAT activity.  Identifying these mechanisms would provide valuable insights 
in our understanding of LD biogenesis and the accumulation of TAG in the context of 
obesity. 
 
Would GPAT inhibition rescue Seipin-deficient lipodystrophy? 
 Based on our hypothesis that in Seipin-deficient cells increased GPAT activity 
underpins the block on adipogenesis, GPAT inhibition may correct Seipin-deficient 
lipodystrophy.  We recently obtained a GPAT inhibitor, of similar structure to those 
described in Background 5, which possess potent GPAT inhibitory activity in our in 
vitro activity assays.  Because Craig Townsend’s group at Yale University reported that 
these compounds also possess inhibitory activity in 3T3L1 cells, we are currently 
evaluating whether the GPAT inhibitor can treat Seipin-deficient lipodystrophy.  
	  	   135	  
Zengying Wu and I are currently performing these assays.  If GPAT inhibition rescues 
adipogenesis in 3T3L1 cells, we plan to treat Seipin-deficient mice with the compound 
and evaluate its efficacy in vivo.  These studies will provide proof-of-concept that GPAT 
inhibition can restore adipogenesis in individuals with Seipin-deficient lipodystrophy.  
Additionally, we have discussed making a double knockout mouse of Seipin and 
GPAT3, however, this approach will require a significant amount of time.  Whether 
microsomal GPAT is involved in the etiology of the acquired lipodystrophies also is an 
intriguing possibility. 
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Public Health Significance 	  
 Despite the significant resources and human capital invested in understanding 
the etiology of obesity and the metabolic syndrome, relatively little progress has been 
made in developing therapeutic treatments.  Clearly, the complex nature of metabolism 
has slowed our progress.  However, results from this dissertation highlighting that 
important aspects of nutrient metabolism are compartmentalized provide valuable 
insights toward our shared treatment goals.  Improving our basic understandings of 
glycerolipid synthesis in this way will strengthen the approaches of research focused on 
the pharmacological inhibition of glycerolipid synthetic enzymes.  These studies will 
inform potential treatment strategies and drug delivery techniques.  Furthermore, these 
discoveries will improve current approaches and inform the work of others in the field.  
Our work revealing the relationship between Seipin and GPAT, suggests that GPAT 
inhibition might be a suitable strategy for treating type 2 congenital generalized 
lipodystrophy.  Although this lipodystrophy only affects a small proportion of people, the 
insights gained from understanding the basic biology of adipose tissue can be applied in 
other areas of research related to obesity. 
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